膵・胆道疾患診療の最前線

出版社： 中山書店
著者：
発行日： 2018-03-15
分野： 臨床医学：内科  >  消化器一般
ISBN： 9784521744452
電子書籍版： 2018-03-15 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

13,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

13,200 円(税込)

購入する

商品紹介

超高齢社会と診断技術の進歩により患者数が増加している膵・胆道疾患はもはやまれな疾患ではない．消化器専門医の責務として，増えつづける膵癌，胆道癌などの悪性腫瘍，重症化すると死亡率が上昇する急性膵炎，胆石症による胆嚢炎・胆管炎，悪性化の評価が難しい膵嚢胞性腫瘍，IgG4関連疾患と位置づけられる自己免疫性膵炎については，十分な知識と診断・治療法を知っておく必要がある．

目次

  • I章　膵・胆道疾患総論
    　膵疾患の疾患概念
    　胆道疾患の疾患概念
    　疫学
    　病態生理

    II章　検査・診断
    　鑑別診断の進め方
    　検体検査
    　画像診断
    　生理学的検査
    　病理組織学的検査

    III章　治療法総論
    　薬物治療
    　内視鏡的乳頭括約筋切開術（EST）、バルーン拡張術（EPBD）
    　体外衝撃波結石破砕療法（ESWL）
    　ステント留置術
    　外科手術
    　内視鏡手術（膵胆嚢ドレナージ、ネクロセクトミー）

    IV章　治療法各論
    　膵疾患
    　胆道疾患

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I章 膵・胆道疾患総論

P.7 掲載の参考文献
1) 急性膵炎診療ガイドライン 2015 改訂出版委員会編. 急性膵炎診療ガイドライン 2015. 第4版. 金原出版 ; 2015.
 
2) Ramstedt M. Alcohol and pancreatitis mortality at the population level : experiences from 14 western countries. Addiction 2004 ; 99 : 1255-61.
PubMed
3) 正宗淳ほか. 生活習慣と膵疾患-アルコール性膵炎の実態調査. 膵臓 2012 ; 27 : 106-12.
 
4) Irving HM, et al. Alcohol as a risk factor for pancreatitis : a systematic review and meta-analysis. JOP 2009 ; 10 : 387-92.
PubMed
5) Moreau JA, et al. Gallstone pancreatitis and the effect of cholecystectomy : a population-based cohort study. Mayo Clin Proc 1998 ; 63 : 466-73.
 
6) Diehl AK, et al. Gallstone size and risk of pancreatitis. Arch Intern Med 1997 ; 157 : 1674-8.
PubMed
7) Mounzer R, et al. Comparison of existing clinical scoring systems to predict persistent organ failure in patients with acute pancreatitis. Gastroenterology 2012 ; 142 : 1476-82.
PubMed
8) Ueda T, et al. Utility of the new Japanese severity score and indications for special therapies in acute pancreatitis. J Gastroenterol 2009 ; 44 : 453-9.
PubMed
9) Banks PA, et al. Classification of acute pancreatitis-2012 : revision of the Atlanta classification and definitions by international consensus. Gut 2013 ; 62 : 102-11.
PubMed
10) Yokoe M, et al. Japanese guidelines for the management of acute pancreatitis : Japanese Guidelines 2015. J Hepatobiliary Pancreat Sci 2015 ; 22 : 405-32.
PubMed
P.14 掲載の参考文献
1) 日本膵臓学会. 日本膵臓学会慢性膵炎臨床診断基準 2001. 膵臓 2001 ; 16 : 560-1.
 
2) 厚生労働省難治性膵疾患に関する調査研究班, 日本膵臓学会, 日本消化器病学会. 慢性膵炎臨床診断基準 2009. 膵臓 2009 ; 24 : 645-6.
 
3) 日本消化器病学会編. 慢性膵炎診療ガイドライン 2015. 改訂第2版. 南江堂 ; 2015.
 
P.18 掲載の参考文献
1) 下瀬川徹ほか. 自己免疫性膵炎の国際コンセンサス診断基準. 膵臓 2011 ; 26 : 684-98.
 
2) Okazaki K, et al. Recent advances in the concept and diagnosis of autoimmune pancreatitis and IgG4-related disease. J Gastroenterol 2011 ; 46 : 277-88.
PubMed
3) Kamisawa T, Okamoto A. Autoimmune pancreatitis : proposal of IgG4-related sclerosing disease. J Gastroenterol 2006 ; 41 : 613-25.
PubMed
4) 日本膵臓学会・厚生労働省難治性膵疾患に関する調査研究班. 自己免疫性膵炎臨床診断基準 2011. 膵臓 2012 ; 27 : 17-25.
 
P.27 掲載の参考文献
1) 日本膵臓学会編. 膵癌取扱い規約. 第7版. 金原出版 ; 2016.
 
2) 厚生労働省平成26年人口動態統計月報年計 (概数) の概況. http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai14/dl/gaikyou26.pdf
 
3) 国立がん研究センターがん情報サービス. 2016年のがん統計予測. がん情報サービス がん登録・統計 http://ganjoho.jp/reg_stat/statistics/stat/short_pred.html
 
4) Yachida S, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010 ; 467 : 1114-7.
PubMed
5) Heiken JP, et al. Pancreatic cancer. Contemporary Issues in Cancer Imaging. Cambridge University Press ; 2009.
 
6) Macgregor-Das AM, Iacobuzio-Donahue CA. Molecular pathways in pancreatic carcinogenesis. J Surg Oncol 2013 ; 107 : 8-14.
PubMed
7) 谷内田真一. ゲノム進化からみた膵がん. 医学のあゆみ 2015 ; 252 : 851-6.
 
8) Yachida S, et al. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin Cancer Res 2012 ; 18 : 6339-47.
PubMed
9) 日本膵臓学会編. 膵癌取扱い規約. 第6版. 金原出版 ; 2009.
 
10) Yoshioka H, et al. Therapeutic neurotomy on head of pancreas for relief of pain due to chronic pancreatitis : a new technical procedure and its results. AMA Arch Surg 1958 ; 76 : 546-54.
PubMed
11) National Comprehensive Cancer Network (NCCN) Practice Guidelines for pancreatic cancer. [Available at : http://www.nccn.org/clinical asp (free registration is required for login)]
 
12) Kato H, et al. Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer : a multi-institutional survey by the Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2013 ; 20 : 601-10.
 
P.34 掲載の参考文献
1) 田中雅夫. IPMN/MCN国際診療ガイドライン 2012年版. 医学書院 ; 2012.
 
2) 日本膵臓学会編. 膵癌取扱い規約. 第7版. 金原出版 ; 2016.
 
3) 鈴木裕ほか. IPMN, MCTにおける全国症例調査の分析と現状おける問題点. 膵臓 2013 ; 18 : 653-63.
 
4) Adsay NV, et al. Intraductal neoplasm of the pancreas. Bosman FT, et al, eds. WHO Classification of Tumours of the Digestive System ; World Hearth Organization of Tumours. 4th ed. IARC Press ; 2010. p.304-13.
 
5) Tanaka M, et al. Revision of international Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 2017 ; 17 : 738-53.
PubMed
6) Compagno J, Oertel JE. Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma) : a clinicopathologic study of 41 cases. Am J Clin Pathol 1978 ; 69 : 573-80.
PubMed
7) Zamboni G, et al. Mucinous cystic neoplasm of the pancreas. Bosman FT, et al, eds. WHO Classification of Tumours of the Digestive System ; World Hearth Organization of Tumours. 4th ed. IARC Press ; 2010. p.236-8.
 
8) Compagno J, Oertel JE. Microcystic adenomas of the pancreas (glycogen-rich cystadenomas) : a clinicopathologic study of 34 cases. Am J Clin Pathol 1978 ; 69 : 289-98.
PubMed
9) Hodgkinson DJ, et al. Pancreatic cystadenoma : a clinicopathologic stydy of 45 cases. Arch Surg 1978 ; 113 : 512-9.
 
10) Terris B, et al. Serous neoplasm of the pancreas. Bosman FT, et al, eds. WHO Classification of Tumours of the Digestive System ; World Hearth Organization of Tumours. 4th ed. IARC Press ; 2010. p.296-9.
 
11) Kimura W, et al. Multicenter Study of Serous Cystic Neoplasm of the Japan Pancreas Society. Pancreas 2012 ; 41 : 380-7.
PubMed
12) Frantz VK. Tumors of the pancreas. Atlas of tumor pathology 1st series. Fascicles 27 and 28. Amed Forces Institute of Pathology ; 1959. p.32-3.
 
13) Tanaka Y, et al. Frequent β-Catenin mutation and cytoplasmic/nuclear accumulation in pancreatic solid-pseudopapillary neoplasm. Cancer Res 2001 ; 61 : 8401-4.
 
14) 吉岡正智ほか. 膵solid-pseudopapillary tumorの臨床病理学的特徴と外科的治療-本邦報告302例と自験6例について. 胆と膵 2001 ; 22 : 45-52.
 
P.40 掲載の参考文献
1) Ito T, et al. Pancreatic neuroendocrine tumors : clinical features, diagnosis and medical treatment : advances. Best Pract Res Clin Gastroenterol 2012 ; 26 : 737-53.
PubMed
2) Falconi M, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 2016 ; 103 : 153-71.
PubMed
3) 日本膵神経内分泌腫瘍研究会 (JNETS) 膵・消化管神経内分泌腫瘍診療ガイドライン作成委員会. 膵・消化管神経内分泌腫瘍 (NET) 診療ガイドライン 2015年. 第1版. 2015.
 
4) Ito T, et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan : a nationwide survey analysis. J Gastroenterol 2015 ; 50 : 58-64.
PubMed
5) Rindi G, et al. The 2010 WHO classification of digestive neuroendocrine neoplasms : a critical appraisal four years after its introduction. Endocr Pathol 2014 ; 25 : 186-92.
PubMed
6) Sorbye H, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3) : The NORDIC NEC study. Annals of Oncology 2013 ; 24 : 152-60.
 
7) Lee L, et al. Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms : a single-center retrospective study. Jpn J Clin Oncol 2015 ; 45 : 1131-8.
PubMed
8) Igarashi H, et al. Pancreatic involvement in Japanese patients with von Hippel-Lindau disease : results of a nationwide survey. J Gastroenterol 2014 ; 49 : 511-6. Epub 2013 Mar 31.
 
9) Hijioka M, et al. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors. Cancer Sci 2014 ; 105 : 1464-71.
PubMed
10) 窪田和雄. 核医学の最先端-神経内分泌腫瘍の核医学. PET Journal 2015 ; 30 : 21-5.
 
11) Fujimori N, et al. Efficacy of endoscopic ultrasonography and endoscopic ultrasonography-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors. Scand J Gastroenterol 2016 ; 51 : 245-52.
PubMed
12) Farrell JM, et al. Pancreatic neuroendocrine tumors : accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria. Cancer Cytho 2014 ; 122 : 770-8.
PubMed
P.45 掲載の参考文献
1) 急性胆管炎・胆嚢炎診療ガイドライン改訂出版委員会編. 急性胆管炎・胆嚢炎の診療ガイドライン 2013. 医学図書出版 ; 2013.
 
P.50 掲載の参考文献
1) 田妻進. 胆石症の診断と治療-エビデンスに基づいて. 胆道 2015 ; 29 : 17-24.
 
2) 谷村弘ほか. 「胆石調査プロジェクト報告」1997年度胆石全国調査報告. 胆道 1998 ; 12 : 276-93.
 
3) 日本消化器病学会編. 胆石症診療ガイドライン. 南江堂 ; 2009.
 
4) Yu IJ, et al. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest 2002 ; 110 : 671-80.
 
5) Repa JJ, et al. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem 2002 ; 277 : 18793-800.
 
6) 大屋敏秀, 田妻進. 胆石と肥満・生活習慣病. 胆と膵 2012 ; 33 : 1211-6.
 
7) Maki T. Pathogenesis of calcium bilirubinate gallstones : role of E. coli, beta-glucuronidase and coagulation by inorganic ions, polyelectrolytes and agitation. Ann Surg 1966 ; 164 : 90-100.
PubMed
8) Ringel J, Lohr M. The muc gene family : their role in diagnosis and early detection of pancreatic cancer. Mol Cancer 2003 ; 2 : 9.
PubMed
9) Zen Y, et al. Lipopolysaccharide induces overexpression of MUC 2 and MUC 5 AC in cultured biliary epithelial cells. Am L Payhol 2002 ; 161 : 1475-84.
 
10) 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班編. 肝内結石症の診療ガイド. 文光堂 ; 2011.
 
11) 沼田義弘ほか. 胆石の危険因子の検討. 胆道 2015 ; 29 : 219-25.
 
P.55 掲載の参考文献
1) 日本肝胆膵外科学会編. 臨床・病理 胆道癌取扱い規約. 第6版. 金原出版 ; 2013.
 
2) 日本肝胆膵外科学会胆道癌診療ガイドライン作成委員会編. エビデンスに基づいた胆道癌診療ガイドライン. 改訂第2版. 医学図書出版 ; 2014.
 
3) Valle J, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010 ; 362 : 1273-81. doi : 10.1056/NEJMoa0908721.
 
4) Kato A, et al. Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery. Ann Surg Oncol 2015 ; 22 Suppl 3 : S1093-9. doi : 10.1245/s10434-015-4768-9.
 
5) Nagino M, et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer : surgical outcome and long-term follow-up. Ann Surg 2006 ; 243 : 364.
PubMed
6) Miyazaki M, et al. One hundred seven consecutive surgical resections for hilar cholangiocarcinoma of Bismuth types II, III, IV between 2001 and 2008. J Hepatobiliary Pancreat Sci 2010 ; 17 : 470-5. doi : 10.1007/s00534-009-0207-2.
 
7) Nagakawa T, et al. Biliary tract cancer treatment : results from the Biliary Tract Cancer Statistics Registry in Japan. J Hepatobiliary Pancreat Surg 2002 ; 9 : 569-75.
PubMed
8) Miyakawa S, et al. Biliary tract cancer treatment : 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg 2009 ; 16 : 1-7. doi : 10.1007/s00534-008-0015-0.
 
9) Ishihara S, et al. Biliary tract cancer registry in Japan from 2008 to 2013. J Hepatobiliary Pancreat Sci 2016 ; 23 : 149-57. doi : 10.1002/jhbp.314.
 
P.62 掲載の参考文献
1) 下瀬川徹ほか. 急性膵炎, 重症急性膵炎の全国調査. 厚生労働科学研究費補助金難治性疾患等克服研究事業難治性膵疾患に関する調査研究. 平成25年度総括・分担研究報告書. 2014. p.51-6.
 
2) 急性膵炎診療ガイドライン 2015 改訂出版委員会編. 急性膵炎診療ガイドライン 2015. 第4版. 金原出版 ; 2015.
 
3) Irving HM, et al. Alcohol as a risk factor for pancreatitis : a systematic review and meta-analysis. JOP 2009 ; 10 : 387-92.
PubMed
4) 下瀬川徹ほか. 慢性膵炎の実態に関する全国調査. 厚生労働科学研究費補助金難治性疾患等克服研究事業難治性膵疾患に関する調査研究. 平成25年度総括・分担研究報告書. 2014. p.167-72.
 
5) 正宗淳ほか. 【膵炎大全～もう膵炎なんて怖くない～】膵炎の概念と分類 膵炎の疫学 全国調査より. 胆と膵 2014 ; 35 : 1011-4.
 
6) 日本消化器病学会編. 慢性膵炎ガイドライン 2015. 改訂第2版. 南江堂 ; 2015.
 
7) 厚生労働省難治性膵疾患に関する調査研究班. 慢性膵炎臨床診断基準 2009. 膵臓 2009 ; 24 : 645-6.
 
8) 正宗淳ほか. 早期慢性膵炎の全国調査. 厚生労働科学研究費補助金難治性疾患等克服研究事業難治性膵疾患に関する調査研究. 平成27年度総括・分担研究報告書. 2016. p.186-90.
 
9) 大槻眞ほか. 慢性膵炎登録患者の予後および死因に関する検討. 厚生労働科学研究費補助金難治性疾患克服研究事業, 平成17～19年度総合研究報告書. 2008. p.153-7.
 
10) 急性胆管炎・胆嚢炎診療ガイドライン改訂出版委員会編. 急性胆管炎・胆嚢炎診療ガイドライン 2013. 第2版. 医学図書出版 ; 2013.
 
11) 小林康人ほか. 【胆道の疾患】 胆石症の疫学と胆道癌との関連性. 病理と臨床 2003 ; 21 : 19-23.
 
12) 井上真奈美ほか. 【膵癌・胆道癌の前癌病変, リスクファクターを探る】 胆石症と肥満からみた胆道癌のリスク 厚生労働省研究班による多目的コホート研究の結果から. 胆と膵 2010 ; 31 : 177-9.
 
13) 国立がん研究センターがん情報サービス「がん登録・統計」http://ganjoho.jp/reg_stat/statistics/dl/index.html
 
14) Egawa S, et al. Japan Pancreatic Cancer Registry ; 30th year anniversary : Japan Pancreas Society. Pancreas 2012 ; 41 : 985-92.
PubMed
15) 全がん協加盟施設の生存率共同調査 http://www.gunma-cc.jp/sarukihan/seizonritu/seizonritu2007.html
 
16) Katanoda K, et al. An updated report on the trends in cancer incidence and mortality in Japan, 1958-2013. Jpn J Clin Oncol 2015 ; 5 : 390-401.
PubMed
17) Ishihara S, et al. Biliary tract cancer registry in Japan from 2008 to 2013. J Hepatobiliary Pancreat Sci 2016 ; 23 : 149-57.
PubMed
18) 山田眞一郎ほか. 【膵癌・胆道癌-基礎と臨床の最新研究動向】 胆道癌 腺癌 胆管癌 胆管癌の危険因子. 日本臨床 2015 ; 73 : 618-21.
 
P.67 掲載の参考文献
1) 正宗淳ほか. 慢性膵炎. 下瀬川徹ほか編. 専門医のための消化器病学. 第2版. 医学書院 ; 2013. p.593-601.
 
2) Masamune A. Genetics of pancreatitis : the 2014 update. Tohoku J Exp Med 2014 ; 232 : 69-77.
PubMed
3) Kubisch CH, et al. Endoplasmic reticulum stress and the pancreatic acinar cell. Expert Rev Gastroenterol Hepatol 2008 ; 2 : 249-60.
PubMed
4) Witt H, et al. Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat Genet 2013 ; 45 : 1216-20.
PubMed
5) Antonucci L, et al. Basal autophagy maintains pancreatic acinar cell homeostasis and protein synthesis and prevents ER stress. Proc Natl Acad Sci USA 2015 ; 112 : E6166-74.
PubMed
6) Gukovsky I, et al. Inflammation, autophagy, and obesity : common features in the pathogenesis of pancreatitis and pancreatic cancer. Gastroenterology 2013 ; 144 : 1199-209.
PubMed
7) Ooi CY, et al. Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology 2011 ; 140 : 153-61.
PubMed
8) 正宗淳ほか. アルコールと膵炎. 日本消化器病学会雑誌 2012 ; 109 : 1526-34.
 
9) Apte MV, et al. Mechanisms of alcoholic pancreatitis. J Gastroenterol Hepatol 2010 ; 25 : 1816-26.
PubMed
10) Fortunato F, et al. Impaired autolysosome formation correlates with Lamp-2 depletion : role of apoptosis, autophagy, and necrosis in pancreatitis. Gastroenterology 2009 ; 137 : 350-60.
PubMed
11) Pandol SJ, et al. Ethanol diet increases the sensitivity of rats to pancreatitis induced by cholecystokinin octapeptide. Gastroenterology 1999 ; 117 : 706-16.
PubMed
12) Whitcomb DC. Gene-environment factors that contribute to alcoholic pancreatitis in humans. J Gastroenterol Hepatol 2006 ; 21 : S52-5.
PubMed
P.72 掲載の参考文献
1) Nakamura T, et al. Study on pancreatic insufficiency (chronic pancreatitis) and steatorrhea in Japanese patients with low fat intake. Digestion 1999 ; 60 (Suppl 1) : 93-6.
 
2) 日本消化器病学会編. 慢性膵炎診療ガイドライン. 改訂第2版. 南江堂 ; 2015.
 
3) Toouli J, et al. Management of pancreatic exocrine insufficiency : Australian Pancreatic Club recommendations. Med J Aust 2010 ; 193 : 461-7.
 
4) Dominguez-Munoz JE. Pancreatic exocrine insufficiency : diagnosis and treatment. J Gastroentrol Hepatol 2011 ; 26 (Suppl 2) : 12-6.
 
5) Pezzilli R, et al. Exocrine pancreatic insufficiency in adults : a shared position statement of the Italian Association for the Study of Pancreas. World J Gastroentrol 2013 ; 19 : 7930-46.
 
6) Pongprasobchai S. Maldigestion from pancreatic exocrine insufficiency. J Gastroenterol Hepatol 2013 ; 28 (Suppl 4) : 99-102.
 
7) Lohr JM, et al. Synopsis of recent guidelines on pancreatic exocrine insufficiency. United European Gastroenterol J 2013 ; 1 : 79-83.
PubMed
8) Afghani E, et al. An overview of the diagnosis and management of nutrition in chronic pancreatitis. Nutr Clin Pract 2014 ; 29 : 295-311.
PubMed
9) Ledder O, et al. Cystic fibrosis : an update for clinicians. Part 2 : hepatobiliary and pancreatic manifestations. J Gastroenterol Hepatol 2014 ; 29 : 1954-62.
PubMed
10) Gheorghe C, et al. Romanian guidelines on the diagnosis and treatment of exocrine pancreatic insufficiency. J Gastrointestin Liver Dis 2015 ; 24 : 117-23.
PubMed
11) 丹藤雄介ほか. 慢性膵炎患者の栄養アセスメント. 消化と吸収 1997 ; 20 : 136-9.
 
12) 丹藤雄介ほか. 膵外分泌患者における潜在的微量金属欠乏の臨床的検討. 消化と吸収 1997 ; 20 : 97-9.
 
P.75 掲載の参考文献
1) Kawabe K, et al. The current managements of pancreatic diabetes in Japan. Clin J Gastroenterol 2009 ; 2 : 1-8.
PubMed
2) Ito T, et al. Pancreatic diabete in a follow-up survey of chronic pancreatitis in Japan. J Gastroenterol 2007 ; 42 : 291-7.
 
3) Koizumi M, et al. Pancreatic diabetes in Japan. Pancreas 1998 ; 16 : 385-91.
PubMed
4) 日本糖尿病学会糖尿病診断基準検討委員会. 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 1999 ; 42 : 385-404.
 
5) Angelopoulos N, et al. Endocrine pancreatic insufficiency in chronic pancreatitis. Pancreatology 2005 ; 5 : 122-31.
PubMed
6) Larsen S. DM secondary to chronic pancreatitis. Dan Med Bull 1993 ; 40 : 153-62.
 
7) Stone VW, et al. Chronic pancreatitis results of whipple's resection and total pancreatectomy. Arch Surg 1988 ; 123 : 815-9.
 
8) Kahl S, et al. Exocrine and endocrine pancreatic insufficiency after pancreatic surgery. Best Pract Res Clin Gastroenterol 2004 ; 18 : 947-55.
PubMed
9) 伊藤鉄英ほか. 膵性糖尿病と予後. 肝胆膵 2006 ; 53 : 573-81.
 
10) 河邉顕ほか. 膵性糖尿病の強化インスリン治療. 胆と膵 2011 ; 32 : 493-7.
 
P.79 掲載の参考文献
1) Hruban RH, et al. Progression model for pancreatic cancer. Clin Cancer Res 2000 ; 6 : 2969-72.
PubMed
2) Hruban RH, et al. Pancreatic intraepithelial neoplasia : a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001 ; 25 : 579-86.
PubMed
3) Basturk O, et al. A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. Am J Surg Pathol 2015 ; 39 : 1730-41.
PubMed
4) Zen Y, et al. Proposal of histological criteria for intraepithelial atypical/proliferative biliary epithelial lesions of the bile duct in hepatolithiasis with respect to cholangiocarcinoma : preliminary report based on interobserver agreement. Pathol Int 2005 ; 55 : 180-8.
PubMed
5) Bailey P, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016 ; 531 : 47-52.
PubMed
6) Nakamura H, et al. Genomic spectra of biliary tract cancer. Nat Genet 2015 ; 47 : 1003-10.
PubMed
7) Furukawa T. Impacts of activation of the mitogen-activated protein kinase pathway in pancreatic cancer. Front Oncol 2015 ; 5 : 23.
PubMed
8) Hingorani SR, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003 ; 4 : 437-50.
PubMed
9) Hsu M, et al. KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas. Cancer 2013 ; 119 : 1669-74.
PubMed
10) Kanda M, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 2012 ; 142 : 730-3 e9.
 
11) Vogelstein B, et al. Surfing the p53 network. Nature 2000 ; 408 : 307-10.
PubMed
12) Zhu J, et al. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature 2015 ; 525 : 206-11.
PubMed
13) Waddell N, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015 ; 518 : 495-501.
PubMed
14) Hingorani SR, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005 ; 7 : 469-83.
PubMed
15) Sato Y, et al. Histological characterization of biliary intraepithelial neoplasia with respect to pancreatic intraepithelial neoplasia. Int J Hepatol 2014 ; 2014 : 678260.
PubMed
16) Furukawa T, et al. Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Mod Pathol 2005 ; 18 : 1034-42.
PubMed
17) Blackford A, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res 2009 ; 15 : 4674-9.
PubMed
P.83 掲載の参考文献
1) 日本消化器病学会編. 胆石症診療ガイドライン 2016. 改訂第2版. 南江堂 ; 2016.
 
2) Hay DW, et al. Pathophysiology and pathogenesis of cholesterol gallstone formation. Semi Liver Dis 1990 ; 10 : 159-70.
 
3) Berge KE, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000 ; 290 : 1771-5.
PubMed
4) Smith AJ, et al. Hepatocyte-specific expression of the human MDR3 P-glycoprotein gene restores the biliary phosphatidylcholine excretion absent in mdr2 (-/-). Hepatology 1998 ; 28 : 530-36.
PubMed
5) Gerloff T, et al. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 1998 ; 273 : 10046-50.
 
6) Temel RE, et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest 2007 ; 117 : 1968-78.
PubMed
7) Naureckiene S, et al. Identification of HE1 as the second gene of Niemann-Pick C disease. Science 2000 ; 290 : 2298-301.
 
8) Yamanashi Y, et al. NPC2 regulates biliary cholesterol secretion via stimulation of ABCG5/G8-mediated cholesterol transport. Gastroenterology 2011 ; 140 : 1664-74.
PubMed
9) Lee SP, et al. Role of gallbladder mucus hypersecretion in the evolution of cholesterol gallstones. J Clin Invest 1981 ; 67 : 1712-23.
PubMed
10) Kibe A, et al. Inhibition of cholesterol crystal formation by apolipoproteins in supersaturated model bile. Science 1984 ; 225 : 514-6.
PubMed
11) Maki T. Pathogenesis of calcium bilirubinate gallstone : role of E. coli, beta-glucuronidase and coagulation by inorganic ions, polyelectrolytes and agitation. Ann Surg 1966 ; 164 : 90-100.
PubMed
12) 新谷史明ほか. 胆汁中ムコ物質. 胆と膵 1989 ; 10 : 1335-9.
 
P.87 掲載の参考文献
1) Isayama H, et al. Cholecystitis after metallic stent placement in patients with malignant distal biliary obstruction. Clin Gastroenterol Hepatol 2006 ; 4 : 1148-53.
PubMed
2) Nakai Y, et al. Intraductal US in the assessment of tumor involvement to the orifice of the cystic duct by malignant biliary obstruction. Gastrointest Endosc 2008 ; 68 : 78-83.
 
3) Nakai Y, et al. Metallic stent with high axial force as a risk factor for cholecystitis in distal malignant biliary obstruction. J Gastroenterol Hepatol 2014 ; 29 : 1557-62.
PubMed
4) Isayama H, et al. The TOKYO Criteria 2014 for Transpapillary Biliary Stenting. Dig Endosc 2015 ; 27 : 259-64.
PubMed
5) 急性胆管炎・胆嚢炎診療ガイドライン改訂出版委員会編. 急性胆管炎・胆嚢炎診療ガイドライン 2013. 第2版. 医学図書出版 ; 2013.
 
6) Tsujino T, et al. Risk factors for acute suppurative cholangitis caused by bile duct stones. Eur J Gastroenterol Hepatol 2007 ; 19 : 585-8.
 

II章 検査・診断

P.93 掲載の参考文献
1) 日本膵臓学会膵癌診療ガイドライン改訂委員会編. 膵癌診療ガイドライン 2016年版. 金原出版 ; 2016. p.44.
 
2) 日本肝胆膵外科学会, 胆道癌診療ガイドライン作成委員会編. エビデンスに基づいた胆道癌診療ガイドライン. 改訂第2版. 医学図書出版 ; 2014.
 
P.98 掲載の参考文献
1) 急性膵炎診療ガイドライン 2015 改訂出版委員会. 急性膵炎診療ガイドライン 2015. 第4版. 金原出版 ; 2015.
 
2) Mayumi T, et al. Validity of the urinary trypsinogen-2 test in the diagnosis of acute pancreatitis. Pancreas 2012 ; 41 : 869-75.
PubMed
3) 急性胆管炎・胆嚢炎診療ガイドライン改訂出版委員会. 急性胆管炎・胆嚢炎診療ガイドライン 2013. 第2版. 医学図書出版 ; 2013.
 
4) Conwell DL, et al. American Pancreatic Association Practice Guidelines in Chronic Pancreatitis : evidence-based report on diagnostic guidelines. Pancreas 2014 ; 43 : 1143-62.
PubMed
P.103 掲載の参考文献
1) Miyasaka K, Funakoshi A. Cholecystokinin and cholecystokinin receptors : a review article. J Gastroenterol 2003 ; 38 : 1-13.
PubMed
2) Shiratori K, et al. Role of secretin and cholecystokinin in oleic acid-stimulated pancreatic secretion in rats. Gastroenterol Jpn 1990 ; 25 : 104-11.
PubMed
3) Li Y, Owyang C. Vagal afferent pathway mediates physiological action of cholecystokinin on pancreatic enzyme secretion. J Clin Invest 1993 ; 92 : 418-24.
PubMed
4) Shimizu K, et al. The mechanism of inhibitory action of secretin on gastric acid secretion in conscious rats. J Physiol 1995 ; 488 : 501-8.
PubMed
5) Chiba T, et al. Mechanism for increase of gastrin release by secretin in Zollinger-Ellison syndrome. Gastroenterology 1989 ; 96 : 1439-44.
PubMed
6) Chey WY, Chang TM. Secretin : historical perspective and current status. Pancreas 2014 ; 43 : 162-82.
PubMed
7) Boden G, et al. Somatostatin suppresses secretin and pancreatic exocrine secretion. Science 1974 ; 190 : 163-5.
 
8) Lee KY, et al. An important role of endogenous insulin on exocrine pancreatic secretion in rats. Am J Physiol 1990 ; 256 : G246-74.
 
9) Seino Y, et al. GIP and GLP-1, the two incretin hormones : similarities and differences. J Diabetes Invest 2010 ; 1 : 9-23.
 
10) Chey WY, et al. Neural hormonal regulation of exocrine pancreatic secretion. Pancreatology 2001 ; 1 : 320-35.
PubMed
P.106 掲載の参考文献
1) Hamano H, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001 ; 344 : 732-8.
PubMed
2) Hamano H, et al. Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitis. Lancet 2002 ; 359 : 1403-4.
PubMed
3) Shimosegawa T, et al. International Consensus Diagnostic Criteria for Autoimmune Pancreatitis : Guidelines of the International Association of Pancreatology. Pancreas 2011 ; 40 : 352-8.
PubMed
4) Ohara H, et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci 2012 ; 19 : 536-42.
 
5) Kawa S, et al. Autoimmune pancreatitis and IgG4-related disease. In : Rose N, MacKay I, eds. The Autoimmune Diseases. 5th ed. Academic Press ; 2013. p.935-49.
 
6) Taguchi M, et al. Decreased production of immunoglobulin M and A in autoimmune pancreatitis. J Gastroenterol 2009 ; 44 : 1133-9.
 
7) 岡崎和一ほか. 原発性硬化性胆管炎と自己免疫性膵炎における免疫異常. 消化器画像 2005 ; 7 : 347-52.
 
8) Frulloni L, et al. Identification of a novel antibody associated with autoimmune pancreatitis. N Engl J Med 2009 ; 361 : 2135-42.
PubMed
9) Angulo P, et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol 2000 ; 32 : 182-7.
PubMed
10) Roozendaal C, et al. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases. J Hepatol 2000 ; 32 : 734-41.
PubMed
11) Muratori P, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin Exp Immunol 2003 ; 132 : 473-6.
PubMed
P.111 掲載の参考文献
1) Hansson GC, et al. Mouse monoclonal antibodies against human cancer cell lines with specificities for blood group and related antigens : characterization by antibody binding to glycosphingolipids in a chromatogram binding assay. J Biol Chem 1983 ; 258 : 4091-7.
 
2) Liu J, et al. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer 2012 ; 131 : 683-91.
PubMed
3) Ballehaninna UK, et al. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma : an evidence based appraisal. J Gastrointest Oncol 2012 ; 3 : 105-19.
 
4) 日本膵臓学会膵癌診療ガイドライン改訂委員会. 膵癌診療ガイドライン 2016年版. 金原出版 ; 2016.
 
5) NCCN Guidelines Version 1. 2013 Pancreatic Adenocarcinoma.
 
6) Humphris JL, et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol 2012 ; 23 : 1713-22.
PubMed
7) Bauer TM, et al. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy : a pooled analysis of 6 prospective trials. Cancer 2013 ; 119 : 285-92.
PubMed
8) Munigala S, et al. Risk of pancreatic cancer in patients with pancreatic cyst. Gastrointest Endosc 2016 ; 84 : 81-6.
PubMed
9) Kanno A, et al. Prediction of invasive carcinoma in branch type intraductal papillary mucinous neoplasms of the pancreas. J Gastroenterol 2010 ; 45 : 952-9.
PubMed
10) Nishihara S, et al. Molecular genetic analysis of the human Lewis histo-blood group system. J Biol Chem 1994 ; 269 : 29271-8.
PubMed
11) Marrelli D, et al. CA19-9 serum levels in obstructive jaundice : clinical value in benign and malignant conditions. Am J Surg 2009 ; 198 : 333-9.
PubMed
12) Bertino G, et al. Carbohydrate 19.9 antigen serum levels in liver disease. Biomed Res Int 2013 ; 2013 : 531640.
 
13) Schoniger-Hekele M, et al. The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis. Dig Dis Sci 2006 ; 51 : 338-45.
PubMed
14) Narimatsu H, et al. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res 1998 ; 58 : 512-8.
 
15) Fabris C, et al. Serum DU-PAN-2 in the differential diagnosis of pancreatic cancer : influence of jaundice and liver dysfunction. Br J Cancer 1991 ; 63 : 451-3.
 
16) Kiriyama S, et al. Usefulness of a new tumor marker, Span-1, for the diagnosis of pancreatic cancer. Cancer 1990 ; 65 : 1557-61.
PubMed
17) Gold P, et al. Specific carcinoembryonic antigens of the human digestive system. J Exp Med 1965 ; 122 : 467-81.
PubMed
18) Beauchemin N, et al. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev 2013 ; 32 : 643-71.
PubMed
19) Lundin J, et al. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer 1994 ; 69 : 515-9.
PubMed
20) Imaoka H, et al. Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer : a retrospective cohort study. Pancreatology 2016 ; 16 : 859-64.
PubMed
21) Chevinsky AH. CEA in tumors of other than colorectal origin. Semin Surg Oncol 1991 ; 7 : 162-6.
PubMed
22) Greenhalf W, et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst 2014 ; 106 : djt347.
 
P.117 掲載の参考文献
1) 急性膵炎診療ガイドライン 2015 改訂出版委員会編. 急性膵炎診療ガイドライン 2015. 第4版. 金原出版 ; 2015.
 
2) 日本消化器病学会編. 慢性膵炎診療ガイドライン 2015. 改訂第2版. 南江堂 ; 2015.
 
3) 日本消化器病学会編. 胆石症診療ガイドライン 2016. 改訂第2版. 南江堂 ; 2016.
 
4) 急性胆管炎・胆嚢炎診療ガイドライン改訂出版委員会編. 急性胆管炎・胆嚢炎診療ガイドライン 2013. 第2版. 医学図書出版 ; 2013.
 
5) 日本膵臓学会膵癌診療ガイドライン改訂委員会編. 膵癌診療ガイドライン 2016年版. 金原出版 ; 2016.
 
6) 日本肝胆膵外科学会胆道癌診療ガイドライン作成委員会編. エビデンスに基づいた胆道癌診療ガイドライン. 改訂第2版. 医学図書出版 ; 2014.
 
7) 日本医学放射線学会, 日本放射線科専門医会・医会編. 画像診断ガイドライン. 2013年版. 金原出版 ; 2013.
 
P.122 掲載の参考文献
1) Lu DSK, et al. Two-phase helical CT for pancreatic tumors : pancreatic versus hepatic phase enhancement of tumor, pancreas, and vascular structures. Radiology 1996 ; 199 : 697-701.
 
2) 小林剛ほか. Helical CTによる膵癌の診断-撮影法と診断能. 胆と膵 1999 ; 20 : 913-21.
 
3) 糸井隆夫ほか. EUS/IDUSの応用と胆膵臨床の進歩-EUS下穿刺吸引生検 (FNAB) の進歩と膵疾患診断の向上. 胆と膵 2004 ; 25 : 499-507.
 
4) 塚田圭子ほか. 膵管癌診断におけるMRCPの意義. 胆と膵 2000 ; 21 : 467-72.
 
5) 福田晃ほか. 小膵癌の早期発見に関する検討. 膵臓 2004 ; 19 : 567-72.
 
6) Sofuni A, et al. Differential diagnosis of pancreatic tumors using ultrasound contrast imaging. J Gastroenterol 2005 ; 40 : 518-25.
PubMed
7) 祖父尼淳ほか. 造影超音波による小膵癌の描出と診断能の向上. 胆と膵 2005 ; 26 : 515-20.
 
8) 森安史典. マイクロバブルを使った造影超音波診断. 柘植秀樹監修. マイクロバブル・ナノバブルの最新技術. シーエムシー出版 ; 2007. p.250-67.
 
9) 香西和久. Real-time Tissue Elastographyの画像化技術と最新技. 胆と膵 2012 ; 33 : 557-63.
 
10) 祖父尼淳ほか. 胆膵疾患における対外式超音波の新展開-4D超音波およびRVSと併せて. 胆と膵 2009 ; 30 : 703-14.
 
11) 三竹毅. Real-time Virtual Sonographyの開発. MEDIX 2004 ; 40 : 31-5.
 
12) 祖父尼淳ほか. 切除不能膵癌に対する強力集束超音波治療. 膵臓 2015 ; 30 : 199-209.
 
P.127 掲載の参考文献
1) Hirooka Y, et al. Contrast-enhanced endoscopic ultrasonography in digestive diseases. J Gastroenterol 2012 ; 47 : 1063-72.
PubMed
2) Inui K, et al. A newly developed electronic 360° radial scanning echoendoscope. Dig Endosc 2004 ; 16 : S240-4.
 
3) Hirooka Y, et al. Linear and curved-linear (convex) endoscopic ultrasonography : the present situation and roles in the future. Dig Endosc 2001 ; 13 : S49-53.
 
4) 廣岡芳樹ほか. 日本超音波医学会用語・診断基準委員会, 日本超音波医学会膵癌診断基準検討小委員会. 膵癌超音波診断基準. 超音波医学 2013 ; 40 : 511-8.
 
5) 厚生労働省難治性膵疾患に関する調査研究班. 慢性膵炎臨床診断基準 2009. 膵臓 2009 ; 24 : 645-6.
 
6) Ishikawa H, et al. A comparison of image quality between tissue harmonic imaging and fundamental imaging with an electronic radial scanning echoendoscope in the diagnosis of pancreatic diseases. Gastrointest Endosc 2003 ; 57 : 931-6.
PubMed
7) Ohno E, et al. Current status of tissue harmonic imaging in endoscopic ultrasonography (EUS) and EUS-elastography in pancreatobiliary diseases. Dig Endosc 2015 ; 27 Suppl 1 : 68-73.
 
8) Ohno E, et al. Intraductal papillary mucinous neoplasms of the pancreas : differentiation of malignant and benign tumors by endoscopic ultrasound findings of mural nodules. Ann Surg 2009 ; 249 : 628-34.
PubMed
9) Ishikawa T, et al. Usefulness of EUS combined with contrast-enhancement in the differential diagnosis of malignant versus benign and preoperative localization of pancreatic endocrine tumors. Gastrointest Endosc 2010 ; 71 : 951-9.
PubMed
10) Matsubara H, et al. Dynamic quantitative evaluation of contrast-enhanced endoscopic ultrasonography in the diagnosis of pancreatic diseases. Pancreas 2011 ; 40 : 1073-9.
PubMed
11) Itokawa F, et al. EUS elastography combined with the strain ratio of tissue elasticity for diagnosis of solid pancreatic masses. J Gastroenterol 2011 ; 46 : 843-53.
PubMed
12) Iglesias-Garcia J, et al. Quantitative endoscopic ultrasound elastography : an accurate method for the differentiation of solid pancreatic masses. Gastroenterology 2010 ; 139 : 1172-80.
PubMed
13) Giovannini M, et al. Endoscopic ultrasound elastography : the first step towards virtual biopsy? Preliminary results in 49 patients. Endoscopy 2006 ; 38 : 344-8.
PubMed
14) Itoh Y, et al. Quantitative analysis of diagnosing pancreatic fibrosis using EUS-elastography (comparison with surgical specimens). J Gastroenterol 2014 ; 49 : 1183-92.
PubMed
P.134 掲載の参考文献
1) 日本膵臓学会膵癌診療ガイドライン改訂委員会編. 膵癌診療ガイドライン. 2016年版. 金原出版 ; 2016.
 
2) 日本消化器病学会編. 慢性膵炎診療ガイドライン 2015. 改訂第2版. 南江堂 ; 2015.
 
3) 日本肝胆膵外科学会, 胆道癌診療ガイドライン作成委員会編. エビデンスに基づいた胆道癌診療ガイドライン. 改訂第2版. 医学図書出版 ; 2014.
 
4) 日本消化器病学会編. 胆石症診療ガイドライン 2016. 改訂第2版. 南江堂 ; 2016.
 
P.138 掲載の参考文献
1) 日本肝胆膵外科学会, 胆道癌診療ガイドライン作成委員会編. エビデンスに基づいた胆道癌診療ガイドライン. 改訂第2版. 医学図書出版 ; 2014.
 
2) Korrapati P, et al. The efficacy of peroral cholangioscopy for difficult bile duct stones and indeterminate strictures : a systematic review and meta-analysis. Endoscopy International Open 2016 ; 04 : E263-75.
 
3) Koyama K, et al. Percutaneous biliary drainage is oncologically inferior to endoscopic drainage : a propensity score matching analysis in resectable distal cholangiocarcinoma. J Gastroenterol 2016 ; 51 : 608-19.
 
4) Kondo H, et al. Development of fatal systemic gas embolism during direct peroral cholangioscopy under carbon dioxide insufflation. Endoscopy 2016 ; 48 : E215-6.
PubMed
5) Nishikawa T, et al. Preoperative assessment of longitudinal extension of cholangiocarcinoma with peroral video-cholangioscopy : a prospective study. Dig Endosc 2014 ; 26 : 450-7.
PubMed
P.142 掲載の参考文献
1) 日本膵臓学会膵癌診療ガイドライン改訂委員会編. 膵癌診療ガイドライン. 2016年版. 金原出版 ; 2016.
 
2) Bang S, et al. The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 2006 ; 40 : 923-9.
PubMed
3) Ruf J, et al. Detection of recurrent pancreatic cancer : comparison of FDG-PET with CT/MRI. Pancreatology 2005 ; 5 : 266-72.
PubMed
4) Sperti C, et al. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 2007 ; 246 : 932-7.
PubMed
5) Tomimaru Y, et al. Clinical utility of 2- [(18) F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors. Surgery 2016 ; 157 : 269-76.
 
6) Nakajo M, et al. The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and associated extrapancreatic autoimmune lesions. Eur J Nucl Med Mol Imaging 2007 ; 34 : 2088-95.
PubMed
7) Shigekawa M, et al. Is 18F-fluorodeoxyglucose positron emission tomography meaningful for estimating the efficacy of corticosteroid therapy in patients with autoimmune pancreatitis? J Hepatobiliary Pancreat Sci 2009 ; 17 : 269-74.
PubMed
8) 日本肝胆膵外科学会胆道癌診療ガイドライン作成委員会編. 胆道癌診療ガイドライン. 改訂第2版. 医学図書出版 ; 2015.
 
9) Kobayashi S, et al. Diagnostic value of FDG-PET for lymphnode metastases and outcome of surgery for biliary cancer. J Surg Oncol 2011 ; 103 : 223-9.
 
10) Kitajima K, et al. Clinical impact of whole body FDG-PET for recurrent biliary cancer : a multicenter study. Ann Nucl Med 2009 ; 23 : 709-15.
PubMed
11) Kumar R, et al. A role of 18F-FDG PET/CT in detecting recurrent gallbladder carcinoma. Clin Nucl Med 2012 ; 37 : 431-5.
 
12) Lee SW, et al. Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. J Gastroenterol 2010 ; 45 : 560-6.
PubMed
P.146 掲載の参考文献
1) Van de Kamer JH, et al. Rapid method for the determination of fat in feces. J Biol Chem 1949 ; 177 ; 347-55.
PubMed
2) 中村光男. 脂肪便の診断法. 竹内正監, 加嶋敬編. 臨床医のための膵性脂肪便の知識-栄養障害・消化吸収不良改善のために. 医学図書出版 ; 1998. p.20-36.
 
3) 厚生労働省難治性膵疾患に関する調査研究班, 日本膵臓学会, 日本消化器病学会. 慢性膵炎臨床診断基準 2009. 膵臓 2009 ; 24 : 645-6.
 
4) Keim V, et al. Clinical value of a new fecal elastase test for detection of chronic pancreatitis. Clin Lab 2003 ; 49 : 209-15.
PubMed
5) Tando Y, et al. Carbon-13 and its clinical application. Yoshikawa T, Naito Y, editors. Gas Biology Research in Clinical Practice. Karger AG ; 2011. p.112-8.
 
P.149 掲載の参考文献
1) 日本消化器病学会編. 慢性膵炎診療ガイドライン 2015. 改訂第2版. 南江堂 ; 2015.
 
2) 清野裕ほか. 糖尿病の分類と診断基準に関する委員会報告 (国際標準化対応版). 糖尿病 2012 ; 55 : 485-504.
 
3) Seltzer HS, et al. Insulin secretion in response to glycemic stimulus : relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest 1967 ; 46 : 323-35.
PubMed
4) 日本糖尿病学会編. 糖尿病治療ガイド 2014-2015. 文光堂 ; 2014.
 
5) Faber OK, et al. A test for the residual beta-cell function in diabetes mellitus. Diabetes 1977 ; 26 : 605-10.
PubMed
P.153 掲載の参考文献
1) 日本臨床細胞学会編. 細胞診ガイドライン 5 消化器-口腔/唾液腺/消化管/肝胆道系/膵臓. 2015年版. 金原出版 ; 2015.
 
2) 日本膵臓学会膵癌診療ガイドライン改訂委員会編. 膵癌診療ガイドライン. 2016年版. 金原出版 ; 2016.
 
3) Iiboshi T, et al. Value of cytodiagnosis using endoscopic nasopancreatic drainage for early diagnosis of pancreatic cancer. Pancreas 2012 ; 41 : 523-9.
PubMed
4) Mikata R, et al. Clinical usefulness of repeated pancreatic juice cytology via endoscopic naso-pancreatic drainage tube in patients with pancreatic cancer. J Gastroenterol 2012 ; 48 : 866-73.
PubMed
5) 八木岡浩ほか. 胆膵疾患における細胞診・生検材料の採取法と標本の取扱い. 胆と膵 2010 ; 31 : 819-25.
 
6) 栗原俊夫ほか. 胆汁細胞診の正診率を上げるために. 胆と膵 2008 ; 29 : 709-15.
 
7) Itoi T, et al. Preoperative diagnosis and management of thick-walled gallbladder based on bile cytology obtained by endoscopic transpapillary gallbladder drainage tube. Gastrointest Endosc 2006 ; 64 : 512-9.
PubMed
P.158 掲載の参考文献
1) Rabenstein T, et al. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc 2004 ; 59 : 606-13.
 
2) Burnett AS, et al. Sensitivity of endoscopic retrograde cholangiopancreatography standard cytology : 10-y review of the literature. J Surg Res 2013 ; 184 : 304-11.
PubMed
3) Ponchon T, et al. Value of endoscopic brush cytology and biopsies for the diagnosis of malignant bile duct stenosis : results of a prospective study. Gastrointest Endosc 1995 ; 42 : 565-72.
PubMed
4) Pugliese V, et al. Endoscopic retrograde forceps biopsy and brush cytology of biliary stricture : a prospective study. Gastrointest Endosc 1995 ; 42 : 520-6.
PubMed
5) Jaiwala J, et al. Triple tissue sampling at ERCP in malignant biliary obstruction. Gastrointest Endosc 2000 ; 51 : 383-90.
 
6) Bellis MD, et al. Tissue sampling at ERCP in suspected malignant biliary stricture (Part 1). Gastrointest Endosc 2002 ; 56 : 552-61.
 
7) Bellis MD, et al. Tissue sampling at ERCP in suspected malignant biliary stricture (Part 2). Gastrointest Endosc 2002 ; 56 : 720-30.
 
8) Hattori M, et al. Prospective study of bilary cytology in suspected perihilar cholangiocarcinoma. Br J Surg 2011 ; 98 : 704-9.
 
9) Parasher VK, Huibregste K. Endoscopic retrograde wire-guided cytology of malignant biliary stricture using a novel scraping brush. Gastrointest Endosc 1998 ; 48 : 288-90.
 
10) Kubota Y, et al. Endoscopic transpapillary biopsy for diagnosis of patients with pancreaticobiliary ductal stricture. Am J Gastroenterol 1993 ; 88 : 1700-4.
PubMed
11) Sugiyama M, et al. Endoscopic transpapillary bile duct biopsy without sphincterotomy for diagnosing biliary stricture : a prospective comparative study with bile and brush cytology. Am J Gastroenterol 1996 ; 91 : 465-7.
PubMed
12) Schoefl R, et al. Forceps biopsy and brush cytology during endoscopic retrograde cholangiopancreatography for the diagnosis of biliary stenosis. Scand J Gastroenterol 1997 ; 32 : 363-8.
PubMed
13) 長谷部修ほか. 経乳頭的胆管生検・ブラッシング細胞診・胆汁細胞診の比較と併用の意義. 胆と膵 2003 ; 24 : 403-8.
 
14) Dragnov PV, et al. Diagnostic accuracy of conventional and cholangioscopy-guided sampling of indeterminate biliary lesions at the time of ERCP : a prospective, long-term follow-up study. Gastrointest Endosc 2012 ; 75 : 347-53.
 
15) Osanai M, et al. Peroral video cholangioscopy to evaluate indeterminate bile duct lesions and preoperative mucosal cancerous extension : a prospective multicenter study. Endoscopy 2013 ; 45 : 635-42.
PubMed
16) Vasilieva LE, et al. Modern diagnostic approaches to cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2012 ; 11 : 349-59.
PubMed
17) Victor DW, et al. Current endoscopic approach to indeterminate biliary strictures. World J Gastroenterol 2012 ; 18 : 6197-205.
PubMed
P.163 掲載の参考文献
1) 神津照雄ほか. 超音波内視鏡下穿刺術ガイドライン. 日本消化器内視鏡学会監修. 消化器内視鏡ガイドライン. 第3版. 医学書院 ; 2006. p.180-7.
 
2) Hebert-Magee S1, et al. The presence of a cytopathologist increases the diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration cytology for pancreatic adenocarcinoma : a meta-analysis. Cytopathology 2013 ; 24 : 159-71.
 
3) Hikichi T, et al. Endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses with rapid on-site cytological evaluation by endosonographers without attendance of cytopathologists. J Gastroenterol 2009 ; 44 : 322-8.
PubMed
4) 入澤篤志ほか. 膵癌診療の最前線-膵腫瘍に対する超音波内視鏡下穿刺術. 日本消化器病学会誌 2003 ; 100 : 280-91.
 
5) Yoshinaga S, et al. Role of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for diagnosis of solid pancreatic masses. Dig Endosc 2011 ; 23 : 29-33.
PubMed
6) Wiersema MJ, et al. Endosonography-guided fine-needle aspiration biopsy : diagnostic accuracy and complication assessment. Gastroenterology 1997 ; 112 ; 1087-95.
PubMed
7) Ngamruengphong S, et al. Risk of gastric or peritoneal recurrence, and long-term outcomes, following pancreatic cancer resection with preoperative endosonographically guided fine needle aspiration. Endoscopy 2013 ; 45 : 619-26.
 
8) Katanuma A, et al. Tumor seeding after endoscopic ultrasound-guided fine-needle aspiration of cancer in the body of the pancreas. Endoscopy 2012 ; 44 Suppl 2 UCTN : E160-1.
 
9) Sakurada A, et al. A case of curatively resected gastric wall implantation of pancreatic cancer caused by endoscopic ultrasound-guided fine-needle aspiration. Endoscopy 2015 ; 47 Suppl 1 UCTN : E198-9.
 
10) Yamabe A, et al. Rare condition of needle tract seeding after EUS-guided FNA for intraductal papillary mucinous carcinoma. Endosc Int Open 2016 ; 4 : E756-8.
PubMed
11) Kita E, et al. A case of needle tract seeding after EUS-guided FNA in pancreatic cancer, detected by serial positron emission tomography/CT. Gastrointest Endosc 2016 ; 84 : 869-70. [Epub ahead of print]
 

III章 治療法総論

P.170 掲載の参考文献
1) 急性膵炎診療ガイドライン 2015 改訂出版委員会編. 急性膵炎診療ガイドライン 2015. 第4版. 金原出版 ; 2015.
 
2) 厚生労働省難治性膵疾患に関する調査研究班, 日本膵臓学会, 日本消化器病学会. 慢性膵炎臨床診断基準 2009. 膵臓 2009 ; 24 : 645-6.
 
3) 日本消化器病学会編. 慢性膵炎診療ガイドライン 2015. 改訂第2版. 南江堂 ; 2015.
 
4) 急性腹症診療ガイドライン出版委員会編. 急性腹症診療ガイドライン 2015. 医学書院 ; 2015.
 
5) 急性胆管炎・胆嚢炎診療ガイドライン改訂出版委員会編. 急性胆管炎・胆嚢炎診療ガイドライン 2013. 第2版. 医学図書出版 ; 2013.
 
6) Basnayake C, Ratnam D. Blood tests for acute pancreatitis. Aust Prescr 2015 ; 38 : 128-30.
PubMed
7) 日本医真菌学会侵襲性カンジダ症の診断・治療ガイドライン作成委員会編. 日本医真菌学会侵襲性カンジダ症の診断・治療ガイドライン Executive summary集. Medical Mycology Journal 2013 ; 54 : 147-251.
 
8) Ray WA, et al. Prescription of long-acting opioids and mortality in patients with chronic noncancer pain. JAMA 2016 ; 315 : 2415-23.
PubMed
9) Kataoka K, et al. Effects of oral ingestion of the elemental diet in patients with painful chronic pancreatitis in the real-life setting in Japan. Pancreas 2014 ; 43 : 451-7.
PubMed
P.174 掲載の参考文献
1) 石原浪砂ほか. ミニブタ膵外分泌機能不全モデルにおける膵消化酵素補充剤 (リパクレオン(R) 顆粒) と消化酵素剤 (ベリチーム(R) 配合顆粒およびエクセラーゼ(R) 配合顆粒) の脂肪, 蛋白質およびデンプンの消化吸収に対する薬理学的効果の比較試験 (in vivo). 新薬と臨床 2012 ; 61 : 1044-53.
 
2) 日本消化器病学会編. 慢性膵炎診療ガイドライン 2015. 改訂第2版. 南江堂 ; 2015.
 
3) Nojgaard C, et al. Danish patients with chronic pancreatitis have a four-fold higher mortality rate than the Danish population. Clin Gastroenterol Hepatol 2010 ; 8 : 384-90.
 
4) 下瀬川徹ほか. 慢性膵炎の断酒・生活指導指針. 膵臓 2010 ; 25 : 617-81.
 
5) 日本消化器病学会編. 慢性膵炎診療ガイドライン. 南江堂 ; 2009.
 
6) Nusrat S, et al. Pancreatic enzymes for chronic pancreatitis. Cochrane Database Syst Rev 2009 ; 4 : CD006302.
 
7) Kato H, et al. Development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) after pancreaticoduodenectomy : proposal of a postoperative NAFLD scoring system. J Hepatobiliary Pancreat Sci 2010 ; 17 : 296-304.
PubMed
8) Borowitz DS, et al. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. J Pediatr 1995 ; 127 : 681-4.
PubMed
P.177 掲載の参考文献
1) 丹藤雄介ほか. 石灰化慢性膵炎患者の食事療法・薬物療法. 胆と膵 2009 ; 30 : 1361-6.
 
2) 伊藤鉄英ほか. 慢性膵炎-治療. 日内会誌 2009 ; 99 : 56-61.
 
3) 中村光男ほか. 膵性糖尿病患者への対応-食事指導. 膵臓 2010 ; 25 : 660-1.
 
4) Kawabe K, et al. The current managements of pancreatic diabetes in Japan. Clin J Gastroenterol 2009 ; 2 : 1-8.
PubMed
5) 河邉顕ほか. 膵性糖尿病の強化インスリン治療. 胆と膵 ; 32 : 493-7.
 
6) Knop FK, et al. Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. Am J Physiol Endocrinol Metab 2007 ; 292 : E324-30.
PubMed
P.180 掲載の参考文献
1) 日本消化器病学会編. 胆石症診療ガイドライン 2016. 改訂第2版. 南江堂 ; 2016.
 
2) European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol 2016 [Epub ahead of print]
 
3) May GR, et al. Efficacy of bile acid therapy for gallstone dissolution : a meta-analysis of randomized trials. Aliment Pharmacol Ther 1993 ; 7 : 139-48.
PubMed
4) Lee JM, et al. Comparison on response and dissolution rates between ursodeoxycholic acid alone or in combination with chenodeoxycholic acid for gallstone dissolution according to stone density on CT scan : strobe compliant observation study. Medicine 2015 ; 94 : e2037.
PubMed
5) Tomida S, et al. Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones : a cohort analysis. Hepatology 1999 ; 30 : 6-13.
PubMed
6) Salman B, et al. Urgent laparoscopic cholecystectomy is the best management for biliary colic : a prospective randomized study of 75 cases. Dig Surg 2005 ; 22 : 95-9.
 
7) Tsai CJ, et al. Statin use and the risk of cholecystectomy in women. Gastroenterology 2009 ; 136 : 1593-600.
PubMed
8) Tazuma S, et al. A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy. J Clin Gastroenterol 1998 ; 26 : 287-91.
PubMed
9) Lauridsen BK, et al. Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease. Eur Heart J 2015 ; 36 : 1601-8.
PubMed
10) Kishikawa N, et al. Long-term administration of a Niemann-Pick C1-like 1 inhibitor, ezetimibe, does not worsen bile lithogenicity in dyslipidemic patients with hepatobiliary diseases. J Hepatobiliary Pancreat Sci 2016 ; 23 : 125-31.
 
P.186 掲載の参考文献
1) 急性膵炎診療ガイドライン 2015 改訂出版委員会. 急性膵炎診療ガイドライン 2015. 第4版. 金原出版 ; 2015.
 
2) 急性胆管炎・胆嚢炎診療ガイドライン改訂出版委員会編. 急性胆管炎・胆嚢炎診療ガイドライン 2013. 第2版. 医学図書出版 ; 2013.
 
3) Gomi H, et al. TG13 : Antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci 2013 ; 20 : 60-70.
PubMed
4) 廣田衛久, 下瀬川徹, 正宗淳ほか. 日本の急性膵炎診療 : 全国調査2011より. 膵臓 2015 ; 30 : 123-36.
 
5) Nordback I, et al. Early treatment with antibiotics reduces the need for surgery in acute necrotizing pancreatitis : a single center randomizing control study. J Gastrointest Surg 2001 ; 5 : 113-20.
PubMed
6) Working group IAP/APA acute pancreatitis guideline : IAP/APA evidence based Guideline for the management of acute pancreatitis. Pancreatology 2013 ; 13 : e1-15.
 
7) 侵襲性カンジダ症の診断・治療ガイドライン作成委員会編. 日本医真菌学会侵襲性カンジダ症の診断・治療ガイドラインExecutive summary集. Med Mycol J 2013 ; 54 : 147-251.
 
8) Solomkin JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children : guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010 ; 50 : 133-64.
 
9) Bai Y, et al. Prophylactic antibiotics cannot prevent endoscopic retrograde cholangiopancreatography-induced cholangitis : a meta-analysis. Pancreas 2009 ; 38 : 126-30.
PubMed
10) Brand M, et al. Antibiotic prophylaxis for patients undergoing elective endoscopic retrograde cholangiopancreatography. Cochrane Database Syst Rev 2010 ; 10 : CD007345.
PubMed
P.192 掲載の参考文献
1) 日本膵臓学会膵癌診療ガイドライン改訂委員会編. 膵癌診療ガイドライン 2016年版. 金原出版 ; 2016.
 
2) Neoptolemos JP, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004 ; 350 : 1200-10.
PubMed
3) Oettle H, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer : a randomized controlled trial. JAMA 2007 ; 297 : 267-77.
PubMed
4) Ueno H, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer : Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009 ; 101 : 908-15.
 
5) Neoptolemos JP, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection : a randomized controlled trial. JAMA 2010 304 : 1073-81.
PubMed
6) Uesaka K, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer : a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 2016 ; 388 : 248-57.
PubMed
7) Neoptolemos JP, et al. ESPAC-4 : a multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol 2016 ; 34 Suppl : abstr LBA4006.
 
8) Burris HA 3rd, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial. J Clin Oncol 1997 ; 15 : 2403-13.
 
9) Moore MJ, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer : a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007 ; 25 : 1960-6.
 
10) Ueno H, et al. Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan : GEST Study. J Clin Oncol 2013 ; 31 : 1640-8.
PubMed
11) Okusaka T, et al. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci 2011 ; 102 : 425-31.
PubMed
12) Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011 ; 364 : 1817-25.
PubMed
13) Von Hoff DD, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013 ; 369 : 1691-703.
PubMed
14) Okusaka T, et al. Phase II study of FOLFIRINOX for metastatic chemotherapy-naive Japanese pancreatic cancer patients. Cancer Sci 2014 ; 105 : 1321-6.
PubMed
15) Ueno H, et al. Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 2016 ; 77 : 595-603.
PubMed
16) 日本膵臓学会膵癌診療ガイドライン改訂委員会. CQ5-2-1 遠隔転移を有する膵癌に対して推奨される一次化学療法は何か? http://www.suizou.org/pdf/s_CQ5-2-1_03.pdf
 
17) Ueno M, et al. Phase II study of modified FOLFIRINOX for chemotherapy-naive patients with metastatic pancreatic cancer. J Clin Oncol 2016 ; 34 Suppl : abstr #4111.
 
18) 日本肝胆膵外科学会胆道癌ガイドライン作成委員会編. エビデンスに基づいた胆道癌診療ガイドライン. 改訂第2版. 医学図書出版 ; 2014.
 
19) Okusaka T, et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2006 ; 57 : 647-53.
PubMed
20) Furuse J, et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer : a multicenter phase II study. Cancer Chemother Pharmacol 2008 ; 62 : 849-55.
PubMed
21) Valle JW, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours : a multicentre randomised phase II study-The UK ABC-01 Study. Br J Cancer 2009 ; 101 : 621-7.
 
22) Valle J, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010 ; 362 : 1273-81.
PubMed
23) Okusaka T, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer : a comparative multicentre study in Japan. Br J Cancer 2010 ; 103 : 469-74.
 
24) Valle JW, et al. Cisplatin and gemcitabine for advanced biliary tract cancer : a meta-analysis of two randomised trials. Ann Oncol 2014 ; 25 : 391-8.
PubMed
25) Morizane C, et al. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer : a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci 2013 ; 104 : 1211-6.
 
26) Kanai M, et al. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002). Cancer Chemother Pharmacol 2015 ; 75 : 293-300.
PubMed
P.197 掲載の参考文献
1) Fujita N, et al. JESED Study Group. Endoscopic sphincterotomy and endoscopic papillary balloon dilatation for bile duct stones : a prospective randomized controlled multicenter trial. Gastrointest Endosc 2003 ; 57 : 151-5.
 
2) Yasuda I, et al. Long-term outcomes after endoscopic sphincterotomy versus endoscopic papillary balloon dilation for bile duct stones. Gastrointest Endosc 2010 ; 72 : 1185-91.
PubMed
3) 良沢昭銘ほか. 日本消化器内視鏡学会. EST診療ガイドライン. Gastroenterol Endosc 2015 ; 57 : 2721-59.
 
4) 糸井隆夫ほか. ESTとEPBD. 日本消化器内視鏡学会監. 消化器内視鏡ハンドブック. 改訂第2版. 日本メディカルセンター ; 2017. p.475-83.
 
5) 藤本一眞ほか. 抗血栓薬服用者に対する消化器内視鏡診療ガイドライン. Gastroenterol Endosc 2012 ; 54 : 2075-102.
 
6) 厚生労働省難治性膵疾患調査班・日本膵臓学会. ERCP後膵炎ガイドライン 2015. 膵臓 2015 ; 30 : 541-84.
 
7) Osanai M, et al. Safety and long-term outcomes of endoscopic papillary balloon dilation in children with bile duct stones. Gastrointest Endosc 2011 ; 73 : 619-23.
PubMed
8) Ersoz G, et al. Biliary sphincterotomy plus dilation with a large balloon for bile duct stones that are difficult to extract. Gastrointest Endosc 2003 ; 57 : 156-9.
PubMed
9) 糸井隆夫ほか. EPLBD診療ガイドライン. Gastroenterol Endosc 2017 ; 59 : 337-65.
 
P.201 掲載の参考文献
1) 田妻進ほか. 3. 治療- (1) 胆嚢結石CQ3-6ESWLの適応は? 日本消化器病学会編. 胆石症診療ガイドライン 2016. 改訂第2版. 南江堂 ; 2016. p.60-2.
 
2) 五十嵐良典ほか. エキスパートに学ぶ 胆管結石症に対する内視鏡治療. 胆道 2010 ; 24 : 30-4.
 
3) 乾和郎ほか. 膵石症の内視鏡治療ガイドライン 2014. 膵臓 2014 ; 29 : 121-48.
 
4) 奥嶋一武ほか. 体外衝撃波結石破砕療法 (ESWL) による総胆管結石の治療. 日消誌 89 ; 1512-9.
 
5) Inui K, et al. Treatment of pancreatic stones with extracorporeal shock wave lithotripsy : results of a multicenter survey. Pancreas 2005 ; 30 : 26-30.
PubMed
6) 三好広尚ほか. 胆嚢結石に対する体外衝撃波結石破砕療法の長期経過観察成績. 日消誌 2001 ; 98 : 1349-56.
 
P.204 掲載の参考文献
1) 峯徹哉ほか. 【処置具を使いこなす】胆・膵内視鏡-胆道ドレナージ 経乳頭胆管ドレナージに用いる処置具 (チューブステント) を使いこなすコツ. 消化器内視鏡 2015 ; 27 : 1433-143.
 
2) 峯徹哉. 手技の解説-ERCP後膵炎のハイリスク患者に対する膵管ステント留置術の効果. Gastroenterological Endoscopy 2012 ; 54 : 3442-5.
 
3) 峯徹哉ほか. 【急性膵炎】ERCP後膵炎のハイリスク患者に対する膵管ステント留置術-その効果と検証. Intensivist 2011 ; 3 : 728-31.
 
P.209 掲載の参考文献
1) 日本消化器病学会編. 胆石症診療ガイドライン 2016. 改訂第2版. 南江堂 ; 2016.
 
2) Clayton ESJ, et al. Meta-analysis of endoscopy and surgery versus surgery alone for common bile duct stones with the gallbladder in situ. Br J Surg 2006 ; 93 : 1185-91. doi : 10.1002/bjs.5568.
 
3) 日本胆道学会学術委員会. 胆石症に関する2013年度全国調査結果報告. 胆道 2014 ; 4 : 612-7.
 
4) 北野正剛ほか. 内視鏡外科手術に関するアンケート調査-第12回集計結果報告. 日本内視鏡外科学会雑誌 2014 ; 19 : 495-640.
 
5) 先天性胆道拡張症 診断・治療ガイドライン. http://www.jspbm.jp/pdf/CBD-GL.pdf
 
6) 膵・消化管NET ガイドライン. http://jnets.umin.jp/pdf/guideline001_1s.pdf
 
7) 日本消化器病学会編. 慢性膵炎診療ガイドライン 2015. 改訂第2版. 南江堂 ; 2015.
 
8) 日本膵臓学会編. 膵癌取扱い規約. 第7版. 金原出版 ; 2016.
 
9) 日本膵臓学会膵癌診療ガイドライン改訂委員会編. 膵癌診療ガイドライン 2016年版. 第4版. 金原出版 ; 2016.
 
10) Sahora K, et al. NeoGemOx : gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery 2011 ; 149 : 311-20. doi : 10.1016/j.surg.2010.07.048.
 
11) Satoi S, et al. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments : results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2013 ; 20 : 590-600. doi : 10.1007/s00534-013-0616-0.
 
12) 日本肝胆膵外科学会, 胆道癌診療ガイドライン作成委員会編. エビデンスに基づいた胆道癌診療ガイドライン. 改訂第2版. 医学図書出版 ; 2014.
 
13) Otsubo T, et al. Safety-related outcomes of the Japanese Society of Hepato-Biliary-Pancreatic Surgery board certification system for expert surgeons. J Hepatobiliary Pancreat Sci 2017 ; 24 : 252-61. doi : 10.1002/jhbp.444.
 
14) National Clinical Database ホームページ. http://www.ncd.or.jp
 
P.214 掲載の参考文献
1) Banks PA, et al. Classification of acute pancreatitis-2012 : revision of the Atlanta classification and definitions by international consensus. Gut 2013 ; 62 : 102-11.
PubMed
2) 急性膵炎診療ガイドライン 2015 改訂出版委員会編. 急性膵炎診療ガイドライン 2015. 第4版. 金原出版 ; 2015.
 
3) 日本消化器病学会編. 慢性膵炎診療ガイドライン 2015. 改訂第2版. 南江堂 ; 2015.
 
4) 山口武人ほか. 膵管・仮性膵?胞ドレナージ. 日本消化器内視鏡学会卒後教育委員会編. 消化器内視鏡ハンドブック. 日本メディカルセンター ; 2012. p.437-48.
 
5) 厚生労働科学研究費補助金難治性疾患克服研究事業難治性膵疾患に関する調査研究班. 膵炎局所合併症 (膵仮性?胞, 感染性被包化壊死等) に対する診断・治療コンセンサス. 膵臓 2014 ; 29 : 775-818.
 
6) van Santvoort HC, et al. A step-up approach or open necrosectomy for necrotizing pancreatitis. N Engl J Med 2010 ; 362 : 1491-502.
 

IV章 治療法各論

P.223 掲載の参考文献
1) 廣田衛久ほか. 日本の急性膵炎診療 : 全国調査2011より. 膵臓 2015 ; 30 : 123-36.
 
2) Mazaki T, et al. Meta-analysis of prophylactic antibiotic use in acute necrotizing pancreatitis. Br J Surg 2006 ; 93 : 674-84.
PubMed
3) Xiong GS, et al. Role of prophylactic antibiotic administration in severe acute pancreatitis : a meta-analysis. Med Princ Pract 2006 ; 15 : 106-10.
PubMed
4) Jacob AO, et al. Early surgical intervention in severe acute pancreatitis : Central Australian experience. ANZ J Surg 2016 ; 86 : 805-10. doi : 10.1111/ans.12707.
 
5) Bladley EL III. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg 1993 ; 128 : 586-90.
 
6) Banks P, et al. Classification of acute pancreatitis-2012 : revision of the Atlanta classification and definitions by international consensus. Gut 2013 ; 62 : 102-11.
PubMed
7) van Santvoort HC, et al. A step-up approach or open necrosectomy for necrotizing pancreatitis. N Engl J Med 2010 ; 362 : 1491-1502.
 
P.231 掲載の参考文献
1) 日本消化器病学会編. 慢性膵炎診療ガイドライン 2015. 改訂第2版. 南江堂 ; 2015.
 
2) Kume K, et al. Alcohol consumption and the risk for developing pancreatitis : a case-control study in Japan. Pancreas 2015 ; 44 : 53-8.
PubMed
3) Masamune A, et al. Sex and age differences in alcoholic pancreatitis in Japan : a multicenter nationwide survey. Pancreas 2013 ; 42 : 578-83. doi : 10.1097/MPA.0b013e31827a02bc.
 
4) Andriulli A, et al. Smoking as a cofactor for causation of chronic pancreatitis : a meta-analysis. Pancreas 2010 ; 39 : 1205-10.
PubMed
5) 下瀬川徹ほか. 慢性膵炎の断酒, 生活指導指針. 膵臓 2010 ; 25 : 617-81.
 
6) Kataoka K, et al. Effects of oral ingestion of the elemental diet in patients with painful chronic pancreatitis in the real-life setting in Japan. Pancreas 2014 ; 43 : 451-7.
PubMed
7) 厚生労働省難治性膵疾患調査研究班・日本膵臓学会. 膵石症の内視鏡治療ガイドライン 2014. 膵臓 2014 ; 29 : 123-48.
 
8) Suzuki Y, et al. Management for pancreatolithiasis : a Japanese multicenter study. Pancreas 2013 ; 42 : 584-8. doi : 10.1097/MPA.0b013e31827308c8.
 
9) 田中雅夫ほか. 慢性膵炎と膵癌の関連性についての調査研究. 厚生労働科学研究費補助金難治性疾患等克服研究事業 (難治性疾患克服研究事業) 難治性膵疾患に関する調査研究. 平成24年度総括・分担研究報告書. 2013. p.166-73.
 
10) Whitcomb DC, et al. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery : a double-blind randomized trial. Am J Gastroenterol 2010 ; 105 : 2276-86.
 
11) 大槻眞ほか. 慢性膵炎登録患者の予後および死因に関する検討. 厚生労働科学研究費補助金難治性疾患克服研究事業難治性膵疾患に関する調査研究. 平成19年度総括・分担研究報告書. 2008. p.98-102.
 
P.237 掲載の参考文献
1) Kamisawa T, et al. IgG4-related disease. Lancet 2015 ; 385 (9976) : 1460-71.
PubMed
2) 厚生労働省難治性膵疾患調査研究班, 日本膵臓学会. 自己免疫性膵炎診療ガイドライン 2013. 膵臓 2013 ; 28 : 715-83.
 
3) Kamisawa T, et al. Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis. J Gastroenterol 2014 ; 49 : 961-70.
PubMed
4) Kamisawa T, et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009 ; 58 : 1504-7.
PubMed
5) Hart PA, et al. Long-term outcomes of autoimmune pancreatitis : a multicenter, international analysis. Gut 2013 ; 62 : 1771-6.
PubMed
6) 神澤輝実ほか. IgG4関連疾患の治療の最前線. 診断と治療 2016 ; 104 : 413-7.
 
7) Kamisawa T, et al. Clinical profile of autoimmune pancreatitis and its histological subtypes. An international multicenter survey. Pancreas 2011 ; 40 : 809-14.
PubMed
8) Ghazale A, et al. Immunoglobulin G4-associated cholangitis : clinical profile and response to therapy. Gastroenterology 2008 ; 134 : 706-15.
PubMed
9) Church NI, et al. Autoimmune pancreatitis : clinical and radiological features and objective response to steroid therapy in a UK series. Am J Gastroenterol 2007 ; 102 : 2417-25.
 
10) Hart PA, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab : the Mayo Clinic experience. Gut 2013 ; 62 : 1607-15.
 
11) Topazian M, et al. Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 2008 ; 6 : 364-6.
PubMed
12) Carruthers MN, et al. Rituximab for IgG4-related disease : a prospective, open-label trial. Ann Rheum Dis 2015 ; 74 : 1171-7.
PubMed
P.245 掲載の参考文献
1) 厚生労働省平成26年人口動態統計月報年計 (概数) の概況. http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai14/dl/gaikyou26.pdf
 
2) 2016年のがん統計予測. がん情報サービス がん登録・統計. http://ganjoho.jp/reg_stat/statistics/stat/short_pred.html
 
3) Gillen S, et al. Preoperative/neoadjuvant therapy in pancreatic cancer : a systematic review and meta-analysis of response and resection percentages. PLoS medicine 2010 ; 7 (4) : e1000267.
PubMed
4) 村田泰洋ほか. 【Neoadjuvant therapy の最新の動向-がんの治療戦略はどのように変わっていくのか】がん種別 術前補助療法の臨床的意義と今後の方向性 膵癌に対するneoadjuvant therapy (解説/特集). 臨床外科 2015 ; 70 : 850-8.
 
5) 村田泰洋ほか. Borderline resectable膵癌の治療戦略. Annual Review OnLine 2015 消化器. 中外医学社 ; p.176-88.
 
6) National Comprehensive Cancer Network (NCCN) Practice Guidelines for pancreatic cancer. Available at : http://www.nccn.org/clinical asp (free registration is required for login)
 
7) 日本膵臓学会編. 膵癌取扱い規約. 第7版. 金原出版 ; 2016.
 
8) Pedrazzoli S, et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas : a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998 ; 228 : 508-17.
 
9) Yeo CJ, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2 : randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002 ; 236 : 355-66 ; discussion 366-8.
 
10) Farnell MB, et al. Pancreas Cancer Working Group. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005 ; 138 : 618-28 ; discussion 628-30.
 
11) Nimura Y, et al. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas : long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 2012 ; 19 : 230-41.
 
12) 日本膵臓学会膵癌診療ガイドライン改訂委員会編. 膵癌診療ガイドライン 2016年版. 金原出版 ; 2016.
 
13) Uesaka K, et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). J Clin Oncol 2013 ; 31 (Suppl 4) : abstr 145.
 
14) Murakami Y, et al. Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection. Cancer Chemother Pharmacol 2013 ; 71 : 419-29.
PubMed
15) Festa V, et al. Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer : a meta-analytical evaluation of prospective studies. JOP 2013 ; 14 : 618-25.
PubMed
16) Satoi S, et al. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments : results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2013 ; 20 : 590-600.
PubMed
P.253 掲載の参考文献
1) Tanaka M, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasm and mucinous cystic neoplasm of the pancreas. Pancreatology 2006 ; 6 : 17-32.
PubMed
2) Tanaka M, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012 ; 12 : 183-97.
PubMed
3) Jang J, et al. Validation of international consensus guidelines for the resection of branch duct-type intraductal papillary mucinous neoplasms. Br J Surg 2014 ; 101 : 686-92.
PubMed
4) Tanaka M, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 2017 ; 17 : 738-53.
PubMed
5) Adsay V, et al. Intraductal neoplasm of the pancreas. Bosman FT, et al, eds. World Health Organization Classification of Tumors, Pathology and Genetics of Tumors of the Digestive System. IARC Press ; 2010. p.304-13.
 
6) Tamura K, et al. Treatment strategy for main duct intraductal papillary mucinous neoplasm of the pancreas based on the assessment of recurrence in the remnant pancreas after resection. Ann Surg 2014 ; 259 : 360-8.
PubMed
7) Hackert T, et al. Main duct intaraductal papillary mucinous neoplasm : high cancer risk in duct diameter of 5 to 9 mm. Ann Surg 2015 ; 262 : 875-81.
PubMed
8) Roch A, et al. Nonoperative management of main pancreatic duct-involved intraductal papillary mucinous neoplasm might be indicated in select patients. J Am Coll Surg 2014 ; 219 : 122-9.
PubMed
9) Kobayashi G, et al. Natural history of branch duct intraductal papillary mucinous neoplasm with mural nodules : a Japan pancreas society multicenter study. Pancreas 2014 ; 43 : 532-8.
PubMed
10) Yamao K, et al. Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian type stroma. Pancreas 2011 ; 40 : 67-71.
PubMed
11) McMillan MT, et al. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN). Cancer 2016 ; 122 : 521-33.
PubMed
12) Tamura K, et al. Distinction of invasive carcinoma derived from intraductal papillary mucinous neoplasms from concomitant ductal adenocarcinoma of the pancreas using molecular biomarkers. Pancreas 2015. Epub ahead of print.
 
13) Ohtsuka T, et al. Follow-up study after resection of intraductal papillary mucinous neoplasm of the pancreas : special references to the multifocal lesions and development of ductal carcinoma in the remnant pancreas. Am J Surg 2012 ; 204 : 44-8.
 
14) Kamata K, et al. Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms. Endoscopy 2014 ; 46 : 22-9.
PubMed
P.259 掲載の参考文献
1) Valsangkar NP, et al. 851 resected cystic tumors of the pancreas : a 33-year experience at the Massachusetts General Hospital. Surgery 2012 ; 152 (3 Suppl 1) : S4-12.
 
2) Kosmahl M, et al. Cystic neoplasms of the pancreas and tumor-like lesions with cystic features : a review of 418 cases and a classification proposal. Virchows Arch 2004 ; 445 : 168-78.
 
3) Compagno J, Oertel JE. Microcystic adenomas of the pancreas (glycogen-rich cystadenomas) : a clinicopathologic study of 34 cases. Am J Clin Pathol 1978 ; 69 : 289-98.
PubMed
4) Jais B, et al. Serous cystic neoplasm of the pancreas : a multinational study of 2622 patients under the auspices of the International Association of Pancreatology and European Pancreatic Club (European Study Group on Cystic Tumors of the Pancreas). Gut 2016 ; 65 : 305-12.
 
5) Kimura W, et al. Multicenter study of serous cystic neoplasm of the Japan pancreas society. Pancreas 2012 ; 41 : 380-7.
PubMed
6) Chu LC, et al. The many faces of pancreatic serous cystadenoma : radiologic and pathologic correlation. Diagn Interv Imaging 2017 ; 98 : 191-202.
PubMed
7) Mukhopadhyay B, et al. Pancreatic lesions in von Hippel-Lindau disease. Clin Endocrinol (Oxf) 2002 ; 57 : 603-8.
PubMed
8) Hammel P, et al. Preoperative cyst fluid analysis is useful for the differential diagnosis of cystic lesions of the pancreas. Gastroenterology 1995 ; 108 : 1230-5.
PubMed
9) Strobel O, et al. Risk of malignancy in serous cystic neoplasms of the pancreas. Digestion 2003 ; 68 : 24-33.
PubMed
10) Hwang HK, et al. Serous cyst adenoma of the pancreas : appraisal of active surgical strategy before it causes problems. Surg Endosc 2012 ; 26 : 1560-5.
PubMed
11) Tseng JF, et al. Serous cystadenoma of the pancreas : tumor growth rates and recommendations for treatment. Ann Surg 2005 ; 242 : 413-9 ; discussion 419-21.
 
12) El-Hayek KM, et al. Rate of growth of pancreatic serous cystadenoma as an indication for resection. Surgery 2013 ; 154 : 794-800 ; discussion 800-2.
 
13) Malleo G, et al. Growth pattern of serous cystic neoplasms of the pancreas : observational study with long-term magnetic resonance surveillance and recommendations for treatment. Gut 2012 ; 61 : 746-51.
PubMed
14) Horvath KD, Chabot JA. An aggressive resectional approach to cystic neoplasms of the pancreas. Am J Surg 1999 ; 178 : 269-74.
PubMed
15) Vassos N, et al. Solid-pseudopapillary neoplasm (SPN) of the pancreas : case series and literature review on an enigmatic entity. Int J Clin Exp Pathol 2013 ; 6 : 1051-9.
 
16) Kloppel G, et al. Pathology and nomenclature of human gastrointestinal neuroendocrine (carcinoid) tumors and related lesions. World J Surg 1996 ; 20 : 132-41.
PubMed
17) Law JK, et al. A systematic review of solid-pseudopapillary neoplasms : are these rare lesions? Pancreas 2014 ; 43 : 331-7.
PubMed
18) Jhala N, et al. Large, clear cytoplasmic vacuolation : an under-recognized cytologic clue to distinguish solid pseudopapillary neoplasms of the pancreas from pancreatic endocrine neoplasms on fine-needle aspiration. Cancer 2008 ; 114 : 249-54.
PubMed
19) Serra S, Chetty R. Revision 2 : an immunohistochemical approach and evaluation of solid pseudopapillary tumour of the pancreas. J Clin Pathol 2008 ; 61 : 1153-9.
PubMed
20) Tang LH, et al. Clinically aggressive solid pseudopapillary tumors of the pancreas : a report of two cases with components of undifferentiated carcinoma and a comparative clinicopathologic analysis of 34 conventional cases. Am J Surg Pathol 2005 ; 29 : 512-9.
 
21) Martin RC, et al. Solid-pseudopapillary tumor of the pancreas : a surgical enigma? Ann Surg Oncol 2002 ; 9 : 35-40.
PubMed
P.266 掲載の参考文献
1) Neuroendocrine Tumors Version 1.2015
 
2) Falconi M, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology 2016 ; 103 : 153-71.
PubMed
3) 日本神経内分泌腫瘍研究会 (JNETS) 膵・消化管神経内分泌腫瘍診療ガイドライン作成委員会編. 膵・消化管神経内分泌腫瘍 (NET) 診療ガイドライン. 2015年 (第1版). 金原出版 ; 2015.
 
4) Yao JC, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 : 514-23.
PubMed
5) Raymond E, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 : 501-13.
PubMed
6) Caplin ME, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014 ; 371 : 224-33.
PubMed
P.272 掲載の参考文献
1) Tazuma S, et al. Report on the 2013 national cholelithiasis survey in Japan. J Hepatobiliary Pancreat Sci 2015 ; 22 : 392-5.
PubMed
2) 厚生労働省難治性の肝・胆道疾患に関する調査研究班編. 肝内結石症の診療ガイド. 文光堂 ; 2011.
 
3) Supe A. Asymptomatic gall stones-revisited. Trop Gastroenterol 2011 ; 32 : 196-203.
PubMed
4) 日本消化器病学会編. 胆石症診療ガイドライン 2016. 改訂第2版. 南江堂 ; 2016.
 
5) Lee JM, et al. Comparison on response and dissolution rates between ursodeoxycholic acid alone or in combination with chenodeoxycholic acid for gallstone dissolution according to stone density on CT scan : strobe compliant observation study. Medicine 2015 ; 94 : e2037.
PubMed
6) 羽生康樹ほか. 医学判断学による胆嚢結石治療法の評価-患者の生活の質および費用効果の観点から. 日本消化器病学会雑誌 1993 ; 90 : 2895-908.
 
7) European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol 2016 [Epub ahead of print]
 
8) Ersoz G, et al. Biliary sphincterotomy plus dilation with a large balloon for bile duct stones that are difficult to extract. Gastrointest Endosc 2003 ; 57 : 156-9.
PubMed
9) Yamamoto R, et al. Ursodeoxycholic acid after bile duct stone removal and risk factors for recurrence : a randomized trial. J Hepatobiliary Pancreat Sci 2016 ; 23 : 132-6.
 
10) 急性膵炎診療ガイドライン 2015 改訂出版委員会編. 急性膵炎診療ガイドライン 2015. 第4版. 金原出版 ; 2015.
 
11) Tazuma S, et al. Clinical features of hepatolithiasis : analyses of multicenter-based surveys in Japan. Lipids Health Dis 2015 ; 14 : 129.
PubMed
P.277 掲載の参考文献
1) 急性胆道炎の診療ガイドライン改訂出版委員会編. 急性胆管炎・胆嚢炎診療ガイドライン 2013. 第2版. 医学図書出版 ; 2013.
 
2) Kogure H1, et al. Fever-based antibiotic therapy for acute cholangitis following successful endoscopic biliary drainage. J Gastroenterol 2011 ; 46 : 1411-7.
 
3) Ito K, et al. Percutaneous cholecystostomy versus gallbladder aspiration for acute cholecystitis : a prospective randomized controlled trial. AJR Am J Roentgenol 2004 ; 183 : 193-6.
PubMed
4) Jang JW, et al. Endoscopic ultrasound-guided transmural and percutaneous transhepatic gallbladder drainage are comparable for acute cholecystitis. Gastroenterology 2012 ; 142 : 805-11.
PubMed
5) Tsujino T, et al. Risk factors for acute suppurative cholangitis caused by bile duct stones. Eur J Gastroen Hepat 2007 ; 19 : 585-8.
 
6) Kawakubo K, et al. Multicenter retrospective study of endoscopic ultrasound-guided biliary drainage for malignant biliary obstruction in Japan. J Hepatobiliary Pancreat Sci 2014 ; 21 : 328-34.
PubMed
P.280 掲載の参考文献
1) 渡辺英伸ほか. 胆道の良性腫瘍・腫瘍性病変の分類・組織診断基準とその問題点. 肝胆膵 1990 ; 21 : 543-9.
 
2) 武藤良弘. Adenomyomatosis. 武藤良弘編. 胆嚢疾患の臨床病理. 医学図書出版 ; 1985. p.141-60.
 
3) 土屋幸浩. 多施設集計報告 胆嚢隆起性病変 (最大径20 mm以下) 503症例の集計成績-大きさ別疾患頻度と大きさ別癌深達度. 日消誌 1986 ; 83 : 2086-7.
 
4) 藤田直孝ほか. 内視鏡的超音波検査法による胆嚢隆起性病変の鑑別診断. 肝胆膵 1991 ; 22 : 751-7.
 
5) Choi JH, et al. Utility of contrast-enhanced harmonic EUS in the diagnosis of malignant gallbladder polyps (with video). Gastrointest Endosc 2013 ; 78 : 484-93.
PubMed
6) Itoi T, et al. Preoperative diagnosis and management of thick-walled gallbladder based on bile cytology obtained by endoscopic transpapillary gallbladder drainage tube. Gastrointest Endosc 2006 ; 64 : 512-9.
PubMed
P.283 掲載の参考文献
1) 武藤良弘ほか. 胆嚢adenomyomatosis (localized type) 37症例の臨床病理. 日本消化器病学会雑誌 1978 ; 75 : 1756-67.
 
2) Albores-Saavedra J, et al. Tumor of the gallbladder, extrahepatic bile ducts, and ampulla of vater. Henson DE, et al, eds. Atlas of Tumor Pathology. 3rd series. Fascicle 27 American Registry of Pathology ; 2000. p.155-8.
 
3) Muguruma N, et al. Adenomyomatosis of the gallbladder as apotential risk factor for gallbladder carcinoma. International Med J 2006 ; 13 : 91-4.
 
4) Miyazaki M, et al. Risk factors for biliary tract and amupullary carcinomas and prophylactic surgery for these factors. J Hepatobiliary Pancreat Surg 2008 ; 15 : 15-24.
PubMed
5) Ootani T, et al. Relationship between gallbladder carcinoma and segmental type of adenomyomatosis of the gallbladder. Cancer 1992 ; 69 : 2647-52.
PubMed
6) Jutras JA. Hyperplasiastic cholecystoses : hickey lecture 1960. Am J Roentgenol Radium Ther Nucl Med 1960 ; 83 : 795-827.
PubMed
7) 武藤良弘. Adenomyomatosis. 武藤良弘編. 胆嚢疾患の臨床病理. 医学図書出版 ; 1985. p.141-60.
 
8) 腹部超音波検診判定マニュアル. 日消がん検診誌 2014 ; 52 : 471-93.
 
9) Nabatame N, et al. High risk of gallbladder carcinoma in elderly patients with segmental adenomyomatosis of the gallbladder. J Exp Clin Cancer Res 2004 ; 23 : 593-8.
PubMed
10) Tanno S, et al. Association anomalous pancreaticobiliary ductal union and adenomyomatosis of the gallbladder. J Gastroenterol Hepatol 1998 ; 13 : 175-80.
PubMed
11) Takuma K, et al. Importance of early diagnosis of pancreaticobiliary maljunction without biliary dilatation. World J Gastroenterol 2012 ; 18 : 3409-14.
PubMed
P.288 掲載の参考文献
1) Jang J-Y, et al. Differential diagnostic and staging accuracies of high resolution ultrasonography, endoscopic ultrasonography, and multidetector computed tomography for gallbladder polypoid lesions and gallbladder cancer. Ann Surg 2009 ; 250 : 943-9. doi : 10.1097/SLA.0b013e3181b5d5fc.
 
2) 日本肝胆膵外科学会胆道癌診療ガイドライン作成委員会編. エビデンスに基づいた胆道癌診療ガイドライン. 改訂第2版. 医学図書出版 ; 2014.
 
3) Engineer R, et al. Neoadjuvant chemoradiation followed by surgery for locally advanced gallbladder cancers : a new paradigm. Ann Surg Oncol 2016 ; 23 : 3009-15. doi : 10.1245/s10434-016-5197-0.
 
4) Kato A, et al. Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery. Ann Surg Oncol 2015 ; 22 Suppl 3 (S3) : S1093-9. doi : 10.1245/s10434-015-4768-9.
 
5) Araida T, et al. Hepatic resection in 485 R0 pT2 and pT3 cases of advanced carcinoma of the gallbladder : results of a Japanese Society of Biliary Surgery survey-a multicenter study. J Hepatobiliary Pancreat Surg 2009 ; 16 : 204-15. doi : 10.1007/s00534-009-0044-3.
 
6) Araida T, et al. Should the extrahepatic bile duct be resected or preserved in R0 radical surgery for advanced gallbladder carcinoma? Results of a Japanese Society of Biliary Surgery Survey : a multicenter study. Surg Today 2009 ; 39 : 770-9. doi : 10.1007/s00595-009-3960-6.
 
7) Horiguchi A, et al. Gallbladder bed resection or hepatectomy of segments 4a and 5 for pT2 gallbladder carcinoma : analysis of Japanese registration cases by the study group for biliary surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2013 ; 20 : 518-24. doi : 10.1007/s00534-012-0584-9.
PubMed
P.293 掲載の参考文献
1) 菅原元ほか. 【膵癌・胆道癌-基礎と臨床の最新研究動向】胆道癌 腺癌 胆管癌 治療 治療のアルゴリズム. 日本臨床 2015 ; 73 (増刊 3 膵癌・胆道癌) : 644-8.
 
2) Pisters PW, et al. Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann Surg 2001 ; 234 : 47-55.
PubMed
3) Takahashi Y, et al. Percutaneous transhepatic biliary drainage catheter tract recurrence in cholangiocarcinoma. Br J Surg 2010 ; 97 : 1860-6.
PubMed
4) Nagino M, et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer : surgical outcome and long-term follow-up. Ann Surg 2006 ; 243 : 364-72.
PubMed
5) Nagino M, et al. Changes in hepatic lobe volume in biliary tract cancer patients after right portal vein embolization. Hepatology 1995 ; 21 : 434-9.
PubMed
6) Miyakawa S, et al. Biliary tract cancer treatment : 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg 2009 ; 16 : 1-7.
PubMed
7) Kimura W, et al. A pancreaticoduodenectomy risk model derived from 8575 cases from a national single-race population (Japanese) using a web-based data entry system : the 30-day and in-hospital mortality rates for pancreaticoduodenectomy. Ann Surg 2014 ; 259 : 773-80.
PubMed
8) 江畑智希ほか. 【膵癌・胆道癌-基礎と臨床の最新研究動向】胆道癌 腺癌 胆管癌 治療 外科的切除 (適応・術式) 中下部 (遠位) 胆管癌. 日本臨床 2015 ; 73 (増刊 3 膵癌・胆道癌) : 654-9.
 
9) Ebata T, et al. Proposal to modify the International Union Against Cancer staging system for perihilar cholangiocarcinomas. Br J Surg 2014 ; 101 : 79-88.
PubMed
10) Ebata T, et al. The concept of perihilar cholangiocarcinoma is valid. Br J Surg 2009 ; 96 : 926-34.
PubMed
11) Nagino M, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma : a single-center 34-year review of 574 consecutive resections. Ann Surg 2013 ; 258 : 129-40.
PubMed
12) Sakamoto Y, et al. Proposal of a new staging system for intrahepatic cholangiocarcinoma : analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan. Cancer 2016 ; 122 : 61-70.
 
13) 日本肝癌研究会編. 臨床・病理 原発性肝癌取扱い規約. 2015. 第6版. 金原出版 ; 2015.
 
14) Valle J, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010 ; 362 : 1273-81.
PubMed
15) Okusaka T, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer : a comparative multicentre study in Japan. Br J Cancer 2010 ; 103 : 469-74.
 
16) Sasaki T, et al. Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2010 ; 65 : 1101-7.
PubMed
17) Furuse J, et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer : a multicenter phase II study. Cancer Chemother Pharmacol 2008 ; 62 : 849-55.
PubMed
18) Miyazaki M, et al. Clinical practice guidelines for the management of biliary tract cancers 2015 : the 2nd English edition. J Hepatobiliary Pancreat Sci 2015 ; 22 : 249-73.
PubMed
19) Isayama H, et al. Clinical benefit of radiation therapy and metallic stenting for unresectable hilar cholangiocarcinoma. World J Gastroenterol 2012 ; 18 : 2364-70.
PubMed
20) Valek V, et al. Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma : a prospective randomised study. Eur J Radiol 2007 ; 62 : 175-9.
PubMed
21) Bosman FT, WHO, International Agency for Research on Cancer. WHO Classification of Tumours of the Digestive System. World Health Organization classification of tumours. 4th ed. International Agency for Research on Cancer ; 2010. p.417
 
22) Onoe S, et al. Prognostic delineation of papillary cholangiocarcinoma based on the invasive proportion : a single-institution study with 184 patients. Surgery 2014 ; 155 : 280-91.
PubMed
23) Onoe S, et al. Clinicopathological significance of mucin production in patients with papillary cholangiocarcinoma. World J Surg 2015 ; 39 : 1177-84.
PubMed
P.298 掲載の参考文献
1) 日本肝胆膵外科学会. 胆道癌診療ガイドライン作成委員会編. エビデンスに基づいた胆道癌診療ガイドライン. 改訂第2版. 医学図書出版 ; 2014.
 
2) 萱原正都. 乳頭部癌に対する膵頭十二指腸切除におけるリンパ節郭清と神経叢郭清のポイント. 外科 2016 ; 78 : 609-13.
 
3) 石原慎ほか. 【十二指腸乳頭部腫瘍をめぐる最近の話題】本邦における十二指腸乳頭癌の現状 1998～2004年登録症例の集計から. 肝胆膵 2007 ; 54 : 737-46.
 
4) Kimura W, et al. Pancreatic carcinoma accompanied by pseudocyst : report of two cases. J Gastroenterol 1994 ; 29 : 786-91.
 
5) 川畑康成, 田島義証. 発生母地からみた十二指腸乳頭部腫瘍の治療戦略. 外科 2016 ; 78 : 571-4.
 
6) 岡野直樹ほか. 十二指腸乳頭部腫瘍に対する内視鏡的治療の適応と成績. 外科 2016 ; 78 : 592-7.
 
7) 辻修二郎, 糸井隆夫. 十二指腸乳頭部腫瘍に対する内視鏡的乳頭切除術. 胆道 2015 ; 29 : 838-46.
 
8) 樋口亮太ほか. 十二指腸乳頭部腫瘍に対する経十二指腸的乳頭部局所切除の実際と成績. 外科 2016 ; 78 : 598-602.
 
9) Valle J, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010 ; 362 : 1273-81.
PubMed
10) Okusaka T, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer : a comparative multicentre study in Japan. Br J Cancer 2010 ; 103 : 469-74.
 
11) Ishihara S, et al. Biliary tract cancer registry in Japan from 2008 to 2013. J Hepatobiliary Pancreat Sci 2016 ; 23 : 149-57.
PubMed
12) 日本肝胆膵外科学会編. 臨床・病理 胆道癌取扱い規約. 第6版. 金原出版 ; 2013.
 
13) Miyakawa S, et al. Biliary tract cancer treatment : 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg 2009 ; 16 : 1-7.
PubMed
P.299 掲載の参考文献
1) Nakazawa T, et al. The 2016 diagnostic criteria. J Gastroenterol 2017 ; 52 : 838-44.
PubMed
P.303 掲載の参考文献
1) Weismann RE, McDonald JR. Cholecystitis : a study of intramural deposits of lipids in twenty-three selected cases. Arch Pathol 1983 ; 45 : 639-57.
 
2) McCoy JJ Jr, et al. Xanthogranulomatous cholecystitis. Report of two cases. J S C Med Assoc 1976 ; 72 : 78-9.
 
3) 豊川秀吉, 權雅憲. 黄色肉芽腫性胆嚢炎の診断と治療. 胆道 2009 ; 23 : 649-53.
 
4) Goshima S, et al. Xanthogranulomatous cholecystitis : diagnostic performance of CT to differentiate from gallbladder cancer. Eur J Radiol 2010 ; 74 : 79-83.
 
5) Ohshima Y, et al. EUS-FNA for suspected malignant biliary strictures after negative endoscopic transpapillary brush cytology and forceps biopsy. J Gastroenterol 2011 ; 46 : 921-8.
PubMed
6) Hijioka S, et al. Can EUS-guided FNA distinguish between gallbladder cancer and xanthogranulomatous cholecystitis? Gastrointest Endosc 2010 ; 72 : 622-7.
PubMed
P.306 掲載の参考文献
1) 日本膵・胆管合流異常研究会, 日本胆道学会編. 膵・胆管合流異常診療ガイドライン. 医学図書出版 ; 2012. p.1-84.
 

ミニレクチャー

P.310 掲載の参考文献
1) 正宗淳ほか. 遺伝性膵炎・家族性膵炎. 別冊日本臨床 2011 ; 膵臓症候群 (第2版) : 189-93.
 
2) 正宗淳. 遺伝性膵炎. 肝胆膵 2016 ; 72 : 727-32.
 
3) Masamune A, et al. Nationwide survey of hereditary pancreatitis in Japan. J Gastroenterol 2017 ; Aug 31. doi : 10.1007/s00535-017-1388-0.
 
4) Whitcomb DC, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 1996 ; 14 : 141-5.
PubMed
5) Masamune A. Genetics of pancreatitis : the 2014 update. Tohoku J Exp Med 2014 ; 232 : 69-77.
PubMed
6) Lowenfels AB, et al. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA 2001 ; 286 : 169-70.
PubMed
7) Gross J. Hereditary pancreatitis. Go VLW, et al, eds. The Exocrine Pancreas Biology, Pathology and Disease. Raven Press ; 1986. p.829-83.
 
8) 大槻眞ほか. 家族性膵炎, 若年性膵炎の疫学調査, および原因遺伝子の解析. 厚生労働省特定疾患対策研究事業 難治性膵疾患に関する調査研究班 平成13年度研究報告書. 2002. p.87-99.
 
P.315 掲載の参考文献
1) Wada K, et al. Clinical importance of Familial Pancreatic Cancer Registry in Japan : a report from kick-off meeting at International Symposium on Pancreas Cancer 2012. J Hepatobiliary Pancreat Sci 2013 Apr 19. [Epub ahead of print]
 
2) Katkhouda N, Mouiel J. Pancreatic cancer in mother and daughter. Lancet 1986 ; 2 : 747.
PubMed
3) Giardiello FM, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000 ; 119 : 1447-53.
PubMed
4) van Lier MG, et al. High cancer risk in Peutz-Jeghers syndrome : a systematic review and surveillance recommendations. Am J Gastroenterol 2010 ; 105 : 1258-64 ; author reply 1265.
PubMed
5) Lynch HT, et al. Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer : a family study. Br J Cancer 1985 ; 52 : 271-3.
PubMed
6) Aarnio M, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999 ; 81 : 214-8.
PubMed
7) Watson P, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008 ; 123 : 444-9.
PubMed
8) Kastrinos F, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009 ; 302 : 1790-5.
PubMed
9) Klein AP, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004 ; 64 : 2634-8.
PubMed
10) Borg A, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000 ; 92 : 1260-6.
PubMed
11) Vasen HF, et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000 ; 87 : 809-11.
 
12) Goldstein AM, et al. Features associated with germline CDKN2A mutations : a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007 ; 44 : 99-106.
PubMed
13) Canto MI, et al. Screening for early pancreatic neoplasia in high-risk individuals : a prospective controlled study. Clin Gastroenterol Hepatol 2006 ; 4 : 766-81.
PubMed
14) Lynch HT, et al. Pancreatic cancer and the FAMMM syndrome. Fam Cancer 2008 ; 7 : 103-12.
PubMed
15) Lal G, et al. Inherited predisposition to pancreatic adenocarcinoma : role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 2000 ; 60 : 409-16.
PubMed
16) Naderi A, Couch FJ. BRCA2 and pancreatic cancer. Int J Gastrointest Cancer 2002 ; 31 : 99-106.
PubMed
17) Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002 ; 94 : 1358-65.
PubMed
18) Hahn SA, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003 ; 95 : 214-21.
PubMed
19) Couch FJ, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007 ; 16 : 342-6.
PubMed
20) Jones S, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009 ; 324 : 217.
PubMed
21) Tischkowitz MD, et al. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology 2009 ; 137 : 1183-6.
PubMed
22) Roberts NJ, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2012 ; 2 : 41-6.
PubMed
23) Matsubayashi H. Familial pancreatic cancer and hereditary syndromes : screening strategy for high-risk individuals. J Gastroenterol 2011 ; 46 : 1249-59.
PubMed
24) Wada K, et al. Screening for pancreatic cancer. Surg Clin North Am 2015 ; 95 : 1041-52.
PubMed
P.318 掲載の参考文献
1) Clarke MF, et al. Cancer stem cells-perspectives on current status and future directions : AACR workshop on cancer stem cell. Cancer Res 2006 ; 66 : 9339-44.
PubMed
2) Li C, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007 ; 67 : 1030-7.
PubMed
3) Hermann PC, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007 ; 1 : 313-23.
PubMed
4) Li C, et al. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 2011 ; 141 : 2218-27.
 
5) Rasheed ZA, et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 2010 ; 102 : 340-51.
PubMed
6) Bailey JM, et al. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in pre-invasive pancreatic cancer. Gastroenterology 2014 ; 146 : 245-56.
 
7) Shi C, et al. CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biol Ther 2010 ; 10 : 1182-90.
PubMed
8) Wang M, et al. Isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell-like properties. Int J Cancer 2011 ; 128 : 72-81.
PubMed
9) Tamai K, et al. Suppressive expression of CD274 increases tumorigenesis and cancer stem cell phenotypes in cholangiocarcinoma. Cancer Sci 2014 ; 105 : 667-74.
PubMed
10) Sainz B Jr, et al. Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Gut 2015 ; 64 : 1921-35.
PubMed
11) Sainz B Jr, et al. ISG15 is a critical microenvironmental factor for pancreatic cancer stem cells. Cancer Res 2014 ; 74 : 7309-20.
PubMed
12) Kordes S, et al. Metformin in patients with advanced pancreatic cancer : a double-blind, randomized, placebo-controlled phase 2 trial. Lancet Oncol 2015 ; 16 : 839-47.
PubMed
13) Sancho P, et al. MYC/PGC-1α balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metab 2015 ; 22 : 590-605.
 
P.321 掲載の参考文献
1) Yamaue H, et al. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer : PEGASUS-PC Study. Cancer Sci 2015 ; 106 : 883-90.
PubMed
2) Miyazawa M, et al. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. Int J Cancer 2017 ; 140 : 973-82.
PubMed
3) Rizvi NA, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015 ; 348 : 124-8.
 
P.323 掲載の参考文献
1) Shapiro AM, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000 ; 343 : 230-8.
PubMed
2) Sakata N, et al. Clinical experiences in the treatment of pancreatic arteriovenous malformation by total pancreatectomy with islet autotransplantation. Transplantation 2013 ; 96 : e38-40.
PubMed
3) Ryan EA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005 ; 54 : 2060-9.
PubMed
4) Bellin MD, et al. Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant 2012 ; 12 : 1576-83.
PubMed
5) Anazawa T, et al. Long-term outcomes of clinical transplantation of pancreatic islets with uncontrolled donors after cardiac death : a multicenter experience in Japan. Transplant Proc 2014 ; 46 : 1980-4.
PubMed
6) Dendo M, et al. Synergistic effect of neutral protease and clostripain on rat pancreatic islet isolation. Transplantation 2015 ; 99 : 1349-55.
PubMed
7) Jimbo T, et al. A novel resting strategy for improving islet engraftment in the liver. Transplantation 2014 ; 97 : 280-6.
PubMed
8) Rafael E, et al. Intramuscular autotransplantation of pancreatic islets in a 7-year-old child : a 2-year follow-up. Am J Transplant 2008 ; 8 : 458-62.
 
P.325 掲載の参考文献
1) Kamisawa T, et al. A new clinicopathological entity of IgG4-related sclerosing disease. J Gastroenterol 2003 ; 38 : 982-4.
 
2) Okazaki K, et al. Recent advances in the concept and pathogenesis of IgG4-related disease in the hepato-bilio-pancreatic system. Gut Liver 2014 ; 8 : 462-70.
PubMed
3) 厚生労働省難治性疾患克服研究事業奨励研究分野IgG4関連全身硬化性疾患の診断法の確立と治療方法の開発に関する研究班, 新規疾患IgG4関連多臓器リンパ増殖性疾患 (IgG4+ MOLPS) の確立のための研究班 : IgG4関連疾患包括診断基準 2011. 日内誌 2012 ; 101 : 795-804.
 
4) Kamisawa T, et al. IgG4-related disease. Lancet 2015 ; 385 : 1460-71.
PubMed
5) Kamisawa T, et al. Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2013 III : treatment and prognosis of autoimmune pancreatitis. J Gastroenterol 2014 ; 49 : 461-70.
 

書評

最近チェックした商品履歴

Loading...